0001628280-23-035957.txt : 20231101 0001628280-23-035957.hdr.sgml : 20231101 20231101160732 ACCESSION NUMBER: 0001628280-23-035957 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231101 DATE AS OF CHANGE: 20231101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 231368253 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20230930.htm 10-Q abt-20230930
000000180012-312023Q3falseP12M00000018002023-01-012023-09-300000001800exch:XCHI2023-01-012023-09-300000001800exch:XNYS2023-01-012023-09-3000000018002023-09-30xbrli:shares00000018002023-07-012023-09-30iso4217:USD00000018002022-07-012022-09-3000000018002022-01-012022-09-30iso4217:USDxbrli:shares00000018002022-12-310000001800us-gaap:CommonStockMember2023-06-300000001800us-gaap:CommonStockMember2022-06-300000001800us-gaap:CommonStockMember2023-07-012023-09-300000001800us-gaap:CommonStockMember2022-07-012022-09-300000001800us-gaap:CommonStockMember2023-09-300000001800us-gaap:CommonStockMember2022-09-300000001800us-gaap:TreasuryStockCommonMember2023-06-300000001800us-gaap:TreasuryStockCommonMember2022-06-300000001800us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000001800us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000001800us-gaap:TreasuryStockCommonMember2023-09-300000001800us-gaap:TreasuryStockCommonMember2022-09-300000001800us-gaap:RetainedEarningsMember2023-06-300000001800us-gaap:RetainedEarningsMember2022-06-300000001800us-gaap:RetainedEarningsMember2023-07-012023-09-300000001800us-gaap:RetainedEarningsMember2022-07-012022-09-300000001800us-gaap:RetainedEarningsMember2023-09-300000001800us-gaap:RetainedEarningsMember2022-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000001800us-gaap:NoncontrollingInterestMember2023-06-300000001800us-gaap:NoncontrollingInterestMember2022-06-300000001800us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000001800us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000001800us-gaap:NoncontrollingInterestMember2023-09-300000001800us-gaap:NoncontrollingInterestMember2022-09-300000001800us-gaap:CommonStockMember2022-12-310000001800us-gaap:CommonStockMember2021-12-310000001800us-gaap:CommonStockMember2023-01-012023-09-300000001800us-gaap:CommonStockMember2022-01-012022-09-300000001800us-gaap:TreasuryStockCommonMember2022-12-310000001800us-gaap:TreasuryStockCommonMember2021-12-310000001800us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000001800us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000001800us-gaap:RetainedEarningsMember2022-12-310000001800us-gaap:RetainedEarningsMember2021-12-310000001800us-gaap:RetainedEarningsMember2023-01-012023-09-300000001800us-gaap:RetainedEarningsMember2022-01-012022-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000001800us-gaap:NoncontrollingInterestMember2022-12-310000001800us-gaap:NoncontrollingInterestMember2021-12-310000001800us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000001800us-gaap:NoncontrollingInterestMember2022-01-012022-09-3000000018002021-12-3100000018002022-09-30abt:segment0000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:USabt:PediatricNutritionalsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMemberabt:PediatricNutritionalsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:USabt:PediatricNutritionalsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMemberabt:PediatricNutritionalsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2022-07-012022-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2023-07-012023-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-07-012023-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2022-07-012022-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:CoreLaboratoryMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:CoreLaboratoryMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:CoreLaboratoryMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:CoreLaboratoryMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMembercountry:US2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMembercountry:US2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2023-07-012023-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-07-012023-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2022-07-012022-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:RapidDiagnosticsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:RapidDiagnosticsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:RapidDiagnosticsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:RapidDiagnosticsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:VascularMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:VascularMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:VascularMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:VascularMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMembercountry:US2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMembercountry:US2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:NeuromodulationMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:NeuromodulationMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:DiabetesCareMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:DiabetesCareMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800country:USus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000001800us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000001800country:USus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000001800us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000001800country:US2023-07-012023-09-300000001800us-gaap:NonUsMember2023-07-012023-09-300000001800country:US2022-07-012022-09-300000001800us-gaap:NonUsMember2022-07-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:EstablishedPharmaceuticalProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:USabt:PediatricNutritionalsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMemberabt:PediatricNutritionalsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:USabt:PediatricNutritionalsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMemberabt:PediatricNutritionalsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2022-01-012022-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2023-01-012023-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-01-012023-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2022-01-012022-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:CoreLaboratoryMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:CoreLaboratoryMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:CoreLaboratoryMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:CoreLaboratoryMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMembercountry:US2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-01-012023-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2022-01-012022-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:PointOfCareMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:RapidDiagnosticsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:RapidDiagnosticsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:USabt:RapidDiagnosticsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMemberabt:RapidDiagnosticsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberabt:ElectrophysiologyMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberabt:HeartFailureMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:VascularMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:VascularMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:VascularMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:VascularMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMembercountry:US2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMembercountry:US2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:NeuromodulationMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:NeuromodulationMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:DiabetesCareMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:USabt:DiabetesCareMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMembercountry:US2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800country:USus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000001800us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000001800country:USus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000001800us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000001800country:US2023-01-012023-09-300000001800us-gaap:NonUsMember2023-01-012023-09-300000001800country:US2022-01-012022-09-300000001800us-gaap:NonUsMember2022-01-012022-09-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2022-07-012022-09-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:MedicalDevicesMemberabt:HeartFailureMember2022-07-012022-09-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:MedicalDevicesMemberabt:HeartFailureMember2022-01-012022-09-300000001800srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2022-01-012022-09-300000001800abt:DiagnosticProductsMember2023-09-300000001800abt:MedicalDevicesMember2023-09-3000000018002023-10-012023-01-012023-09-30xbrli:pure00000018002023-10-012023-09-3000000018002025-10-012023-01-012023-09-3000000018002025-10-012023-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000001800us-gaap:EquitySecuritiesMember2023-09-300000001800us-gaap:EquitySecuritiesMember2022-12-310000001800us-gaap:OtherInvestmentsMember2023-09-300000001800us-gaap:OtherInvestmentsMember2022-12-310000001800us-gaap:EquitySecuritiesMemberabt:StJudeMedicalMember2023-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-012023-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012022-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000001800abt:CardiovascularSystemsIncMember2023-04-270000001800abt:CardiovascularSystemsIncMember2023-04-272023-04-27abt:intangibleAsset0000001800abt:EstablishedPharmaceuticalProductsMember2023-09-300000001800abt:NutritionalProductsMember2023-09-300000001800abt:MedicalDevicesMember2023-01-012023-09-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-01-012023-09-300000001800abt:CostOfGoodsAndServicesSoldMemberabt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-01-012023-09-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000001800us-gaap:SellingGeneralAndAdministrativeExpensesMemberabt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-01-012023-09-300000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2022-12-310000001800abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember2023-09-300000001800us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000001800abt:RestrictedStockAwardsMember2023-01-012023-09-300000001800us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000001800us-gaap:EmployeeStockOptionMember2023-09-300000001800abt:A0875LongTermNotesDue2023Member2023-09-272023-09-27iso4217:EUR0000001800abt:A0875LongTermNotesDue2023Member2023-09-270000001800abt:BigfootBiomedicalMember2023-09-012023-09-300000001800abt:A255LongTermNotesDue2022Member2022-03-152022-03-150000001800abt:A255LongTermNotesDue2022Member2022-03-150000001800us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-09-300000001800us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-09-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-12-310000001800abt:FiveYearTermLoanDue2024Memberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000001800abt:FiveYearTermLoanDue2024Memberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-09-300000001800abt:FiveYearTermLoanDue2024Memberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000001800abt:FiveYearTermLoanDue2024Memberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberabt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:InterestRateSwapMember2023-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberabt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:InterestRateSwapMember2022-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberabt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMember2023-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberabt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMember2022-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberabt:PrepaidExpensesAndOtherReceivablesCurrentMemberus-gaap:InterestRateSwapMember2023-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberabt:PrepaidExpensesAndOtherReceivablesCurrentMemberus-gaap:InterestRateSwapMember2022-12-310000001800us-gaap:FairValueHedgingMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-09-300000001800us-gaap:FairValueHedgingMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-09-300000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-09-300000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-09-300000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-12-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-09-300000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-12-310000001800abt:LongTermDebtExcludingCurrentMaturitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:DebtMember2023-09-300000001800abt:LongTermDebtExcludingCurrentMaturitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:DebtMember2022-12-310000001800abt:CostOfGoodsAndServicesSoldMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000001800abt:CostOfGoodsAndServicesSoldMemberus-gaap:ForeignExchangeForwardMember2022-07-012022-09-300000001800abt:CostOfGoodsAndServicesSoldMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000001800abt:CostOfGoodsAndServicesSoldMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000001800us-gaap:DebtMember2023-07-012023-09-300000001800us-gaap:DebtMember2022-07-012022-09-300000001800us-gaap:DebtMember2023-01-012023-09-300000001800us-gaap:DebtMember2022-01-012022-09-300000001800us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2023-07-012023-09-300000001800us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300000001800us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2023-01-012023-09-300000001800us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300000001800us-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000001800us-gaap:ForeignExchangeForwardMember2022-07-012022-09-300000001800us-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000001800us-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000001800us-gaap:EquitySecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300000001800us-gaap:EquitySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000001800us-gaap:EquitySecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000001800us-gaap:EquitySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2023-09-300000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2022-12-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeForwardMember2023-09-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ForeignExchangeForwardMember2022-12-310000001800us-gaap:ForeignExchangeForwardMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateSwapMember2023-09-300000001800us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:InterestRateSwapMember2022-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000001800us-gaap:FairValueMeasurementsRecurringMember2023-09-300000001800us-gaap:FairValueInputsLevel1Member2023-09-300000001800us-gaap:FairValueInputsLevel2Member2023-09-300000001800us-gaap:FairValueInputsLevel3Member2023-09-300000001800us-gaap:FairValueMeasurementsRecurringMember2022-12-310000001800us-gaap:FairValueInputsLevel1Member2022-12-310000001800us-gaap:FairValueInputsLevel2Member2022-12-310000001800us-gaap:FairValueInputsLevel3Member2022-12-310000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MinimumMember2023-09-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MaximumMember2023-09-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMember2023-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMember2023-07-012023-09-300000001800us-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMember2023-01-012023-09-300000001800us-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000001800us-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000001800us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300000001800us-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000001800abt:NutritionalProductsMember2022-07-012022-09-300000001800abt:NutritionalProductsMember2022-01-012022-09-300000001800abt:MedicalDevicesMember2022-07-012022-09-300000001800abt:MedicalDevicesMember2022-01-012022-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation
I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer x
Accelerated Filer o
Non-Accelerated Filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of September 30, 2023, Abbott Laboratories had 1,736,058,536 common shares without par value outstanding.

Abbott Laboratories
Table of Contents
2


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended Nine Months Ended
September 30September 30
2023202220232022
Net sales$10,143 $10,410 $29,868 $33,562 
Cost of products sold, excluding amortization of intangible assets4,605 4,629 13,419 14,549 
Amortization of intangible assets496 498 1,485 1,517 
Research and development672 782 2,041 2,163 
Selling, general and administrative2,723 2,731 8,225 8,275 
Total operating cost and expenses8,496 8,640 25,170 26,504 
Operating earnings1,647 1,770 4,698 7,058 
Interest expense166 141 478 404 
Interest (income)(97)(55)(296)(95)
Net foreign exchange (gain) loss(10)19 17 16 
Other (income) expense, net(83)(93)(370)(253)
Earnings before taxes1,671 1,758 4,869 6,986 
Taxes on earnings235 323 740 1,086 
Net Earnings$1,436 $1,435 $4,129 $5,900 
Basic Earnings Per Common Share$0.82 $0.82 $2.36 $3.35 
Diluted Earnings Per Common Share$0.82 $0.81 $2.35 $3.32 
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share1,738,700 1,752,968 1,740,255 1,756,209 
Dilutive Common Stock Options9,589 10,685 9,819 11,638 
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,748,289 1,763,653 1,750,074 1,767,847 
Outstanding Common Stock Options Having No Dilutive Effect7,334 5,445 5,474 2,655 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months EndedNine Months Ended
September 30September 30
2023202220232022
Net Earnings$1,436 $1,435 $4,129 $5,900 
Foreign currency translation gain (loss) adjustments(480)(1,008)(393)(1,429)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(1) and $(4) in 2023 and $11 and $36 in 2022
(9)56 (13)172 
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 and $(24) in 2023 and $50 and $96 in 2022
80 213 (23)186 
Other comprehensive income (loss)(409)(739)(429)(1,071)
Comprehensive Income$1,027 $696 $3,700 $4,829 
September 30,
2023		December 31,
2022
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments$(7,126)$(6,733)
Net actuarial (losses) and prior service (costs) and credits(1,506)(1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other152 175 
Accumulated other comprehensive income (loss)$(8,480)$(8,051)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
September 30,
2023		December 31,
2022
Assets
Current Assets:
Cash and cash equivalents$6,709 $9,882 
Short-term investments338 288 
Trade receivables, less allowances of $472 in 2023 and $500 in 2022
6,499 6,218 
Inventories:
Finished products3,847 3,805 
Work in process888 680 
Materials1,915 1,688 
Total inventories6,650 6,173 
Prepaid expenses and other receivables2,468 2,663 
Total Current Assets22,664 25,224 
Investments788 766 
Property and equipment, at cost21,111 20,212 
Less: accumulated depreciation and amortization11,559 11,050 
Net property and equipment9,552 9,162 
Intangible assets, net of amortization9,282 10,454 
Goodwill23,277 22,799 
Deferred income taxes and other assets6,527 6,033 
$72,090 $74,438 
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable$3,961 $4,607 
Salaries, wages and commissions1,479 1,556 
Other accrued liabilities5,347 5,845 
Dividends payable886 887 
Income taxes payable318 343 
Current portion of long-term debt1,051 2,251 
Total Current Liabilities13,042 15,489 
Long-term debt14,477 14,522 
Post-employment obligations, deferred income taxes and other long-term liabilities6,877 7,522 
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
— — 
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2023: 1,987,305,154; 2022: 1,986,519,278
24,727 24,709 
Common shares held in treasury, at cost — Shares: 2023: 251,246,618; 2022: 248,724,257
(15,686)(15,229)
Earnings employed in the business36,920 35,257 
Accumulated other comprehensive income (loss)(8,480)(8,051)
Total Abbott Shareholders’ Investment37,481 36,686 
Noncontrolling Interests in Subsidiaries213 219 
Total Shareholders’ Investment37,694 36,905 
$72,090 $74,438 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended September 30
20232022
Common Shares:
Balance at June 30
Shares: 2023: 1,987,181,491; 2022: 1,985,676,735
$24,612 $24,429 
Issued under incentive stock programs  
Shares: 2023: 123,663; 2022: 242,705
6 12 
Share-based compensation116 123 
Issuance of restricted stock awards(7)(4)
Balance at September 30  
Shares: 2023: 1,987,305,154; 2022: 1,985,919,440
$24,727 $24,560 
Common Shares Held in Treasury:
Balance at June 30
Shares: 2023: 251,823,511; 2022: 234,456,992
$(15,722)$(13,720)
Issued under incentive stock programs  
Shares: 2023: 579,159; 2022: 528,436
36 31 
Purchased  
Shares: 2023: 2,266; 2022: 8,417,107
— (866)
Balance at September 30  
Shares: 2023: 251,246,618; 2022: 242,345,663
$(15,686)$(14,555)
Earnings Employed in the Business:
Balance at June 30$36,355 $34,487 
Net earnings1,436 1,435 
Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47)
(889)(822)
Effect of common and treasury share transactions18 15 
Balance at September 30$36,920 $35,115 
Accumulated Other Comprehensive Income (Loss):
Balance at June 30$(8,071)$(8,706)
Other comprehensive income (loss)(409)(739)
Balance at September 30$(8,480)$(9,445)
Noncontrolling Interests in Subsidiaries:
Balance at June 30$230 $226 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases(17)(17)
Balance at September 30$213 $209 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
6
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Nine Months Ended September 30
20232022
Common Shares:
Balance at January 1
Shares: 2023: 1,986,519,278; 2022: 1,985,273,421
$24,709 $24,470 
Issued under incentive stock programs
Shares: 2023: 785,876; 2022: 646,019
36 36 
Share-based compensation531 572 
Issuance of restricted stock awards(549)(518)
Balance at September 30
Shares: 2023: 1,987,305,154; 2022: 1,985,919,440
$24,727 $24,560 
Common Shares Held in Treasury:
Balance at January 1
Shares: 2023: 248,724,257; 2022: 221,191,228
$(15,229)$(11,822)
Issued under incentive stock programs
Shares: 2023: 4,669,629; 2022: 4,808,575
288 261 
Purchased
Shares: 2023: 7,191,990; 2022: 25,963,010
(745)(2,994)
Balance at September 30
Shares: 2023: 251,246,618; 2022: 242,345,663
$(15,686)$(14,555)
Earnings Employed in the Business:
Balance at January 1$35,257 $31,528 
Net earnings4,129 5,900 
Cash dividends declared on common shares (per share — 2023: $1.53; 2022: $1.41)
(2,668)(2,475)
Effect of common and treasury share transactions202 162 
Balance at September 30$36,920 $35,115 
Accumulated Other Comprehensive Income (Loss):
Balance at January 1$(8,051)$(8,374)
Other comprehensive income (loss)(429)(1,071)
Balance at September 30$(8,480)$(9,445)
Noncontrolling Interests in Subsidiaries:
Balance at January 1$219 $222 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases(6)(13)
Balance at September 30$213 $209 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Nine Months Ended September 30
20232022
Cash Flow From (Used in) Operating Activities:
Net earnings$4,129 $5,900 
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation945 943 
Amortization of intangible assets1,485 1,517 
Share-based compensation530 570 
Trade receivables(424)(409)
Inventories(527)(1,224)
Other, net(1,915)(42)
Net Cash From Operating Activities4,223 7,255 
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment(1,447)(1,167)
Acquisitions of businesses and technologies, net of cash acquired(877)— 
Proceeds from business dispositions40 48 
Sales (purchases) of other investment securities, net(45)(3)
Other20 14 
Net Cash From (Used in) Investing Activities(2,309)(1,108)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other(90)37 
Proceeds from issuance of long-term debt1 7 
Repayments of long-term debt(1,447)(753)
Purchases of common shares(968)(3,110)
Proceeds from stock options exercised133 126 
Dividends paid(2,668)(2,486)
Net Cash From (Used in) Financing Activities(5,039)(6,179)
Effect of exchange rate changes on cash and cash equivalents(48)(173)
Net Increase (Decrease) in Cash and Cash Equivalents(3,173)(205)
Cash and Cash Equivalents, Beginning of Year9,882 9,799 
Cash and Cash Equivalents, End of Period$6,709 $9,594 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
8
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.


Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
9
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended September 30, 2023Three Months Ended September 30, 2022
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $987 $987 $— $1,001 $1,001 
Other— 381 381 — 325 325 
Total— 1,368 1,368 — 1,326 1,326 
Nutritionals —    
Pediatric Nutritionals506 495 1,001 357 470 827 
Adult Nutritionals354 718 1,072 329 639 968 
Total860 1,213 2,073 686 1,109 1,795 
Diagnostics —     
Core Laboratory317 997 1,314 281 938 1,219 
Molecular38 95 133 65 118 183 
Point of Care97 43 140 92 35 127 
Rapid Diagnostics561 301 862 1,273 839 2,112 
Total1,013 1,436 2,449 1,711 1,930 3,641 
Medical Devices —    
Rhythm Management271 292 563 263 270 533 
Electrophysiology246 298 544 225 244 469 
Heart Failure217 67 284 207 51 258 
Vascular251 421 672 213 393 606 
Structural Heart223 264 487 207 213 420 
Neuromodulation188 39 227 156 36 192 
Diabetes Care 544 928 1,472 423 744 1,167 
Total1,940 2,309 4,249 1,694 1,951 3,645 
Other4 — 4 3 — 3 
Total$3,817 $6,326 $10,143 $4,094 $6,316 $10,410 


10
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 3 — Revenue (Continued)
Nine Months Ended September 30, 2023Nine Months Ended September 30, 2022
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,889 $2,889 $— $2,853 $2,853 
Other— 955 955 — 843 843 
Total— 3,844 3,844 — 3,696 3,696 
Nutritionals —    
Pediatric Nutritionals1,472 1,477 2,949 1,108 1,491 2,599 
Adult Nutritionals1,081 2,086 3,167 1,016 2,027 3,043 
Total2,553 3,563 6,116 2,124 3,518 5,642 
Diagnostics —
Core Laboratory917 2,872 3,789 836 2,788 3,624 
Molecular128 293 421 308 507 815 
Point of Care289 127 416 284 110 394 
Rapid Diagnostics1,975 853 2,828 5,436 2,923 8,359 
Total3,309 4,145 7,454 6,864 6,328 13,192 
Medical Devices —
Rhythm Management800 873 1,673 775 830 1,605 
Electrophysiology729 873 1,602 667 773 1,440 
Heart Failure661 199 860 610 167 777 
Vascular733 1,271 2,004 650 1,228 1,878 
Structural Heart652 794 1,446 604 667 1,271 
Neuromodulation528 122 650 456 112 568 
Diabetes Care1,528 2,681 4,209 1,165 2,320 3,485 
Total5,631 6,813 12,444 4,927 6,097 11,024 
Other10 — 10 8 — 8 
Total$11,503 $18,365 $29,868 $13,923 $19,639 $33,562 

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.

Remaining Performance Obligations

As of September 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.2 billion in the Diagnostics segment and approximately $456 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

11
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 3 — Revenue (Continued)
Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2022$500 
Unearned revenue from cash received during the period346 
Revenue recognized related to contract liability balance(292)
Balance at September 30, 2023$554 

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2023 and 2022 were $1.431 billion and $1.429 billion, respectively, and for the nine months ended September 30, 2023 and 2022 were $4.113 billion and $5.876 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2023 includes $302 million of pension contributions and the payment of cash taxes of approximately $1.180 billion. The first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million.

The following summarizes the activity for the first nine months of 2023 related to the allowance for doubtful accounts as of September 30, 2023:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022$262 
Provisions/charges to income22 
Amounts charged off and other deductions(25)
Balance at September 30, 2023$259 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
12
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
The components of long-term investments as of September 30, 2023 and December 31, 2022 are as follows:

(in millions)September 30,
2023		December 31,
2022
Long-term Investments:
Equity securities$566 $558 
Other222 208 
Total$788 $766 

The increase in Abbott’s long-term investments as of September 30, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.

Abbott’s equity securities as of September 30, 2023 include $291 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of September 30, 2023 with a carrying value of $175 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $87 million that do not have a readily determinable fair value.

Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202320222023202220232022
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
Other comprehensive income (loss) before reclassifications(497)(1,008)(9)15 96 278 
Amounts reclassified from accumulated other comprehensive income17 — — 41 (16)(65)
Net current period comprehensive income (loss)(480)(1,008)(9)56 80 213 
Balance at September 30$(7,126)$(7,268)$(1,506)$(2,498)$152 $321 
13
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20232022202320222023 2022
Balance at January 1$(6,733)$(5,839)$(1,493)$(2,670)$175 $135 
Other comprehensive income (loss) before reclassifications(410)(1,429)(6)45 134 289 
Amounts reclassified from accumulated other comprehensive income 17 — (7)127 (157)(103)
Net current period comprehensive income (loss)(393)(1,429)(13)172 (23)186 
Balance at September 30$(7,126)$(7,268)$(1,506)$(2,498)$152 $321 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.

Note 6 — Business Acquisitions

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management even more personal and precise. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

The preliminary allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets of $305 million; non-deductible in-process research and development of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $384 million; net deferred tax assets of approximately $31 million and other net assets of approximately $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $23.3 billion at September 30, 2023 and $22.8 billion at December 31, 2022. Recent business acquisitions increased goodwill by approximately $590 million and foreign currency translation adjustments decreased goodwill by approximately $112 million in the first nine months of 2023. The amount of goodwill related to reportable segments at September 30, 2023 was $2.6 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.8 billion for the Medical Devices segment. There were no reductions of goodwill relating to impairments in the first nine months of 2023.
14
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 7 — Goodwill and Intangible Assets (continued)
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.2 billion as of September 30, 2023 and December 31, 2022, respectively. The gross amount of amortizable intangible assets increased by $305 million due to a recent business acquisition. Accumulated amortization was $19.0 billion and $17.6 billion as of September 30, 2023 and December 31, 2022, respectively. Foreign currency translation adjustments decreased intangible assets by $14 million in the first nine months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were approximately $832 million as of September 30, 2023 and $807 million as of December 31, 2022. Recent business acquisitions increased IPR&D by $80 million. This increase was partially offset by $55 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.

Note 8 — Restructuring Plans

In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the nine months ended September 30, 2023, Abbott recorded employee related severance and other charges of approximately $102 million, of which approximately $31 million was recorded in Cost of products sold, approximately $16 million was recorded in Research and development, and approximately $55 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $29 million related to these restructuring plans.

The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2023:

(in millions)Total
Accrued balance at December 31, 2022$228 
Restructuring charges in 2023102 
Payments and other adjustments(181)
Accrued balance at September 30, 2023$149 

Note 9 — Incentive Stock Programs

In the first nine months of 2023, Abbott granted 1,986,671 stock options, 463,856 restricted stock awards and 4,927,476 restricted stock units under its incentive stock program. At September 30, 2023, approximately 74 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2023 is as follows:

OutstandingExercisable
Number of shares 29,342,041 24,718,236 
Weighted average remaining life (years)
5.04.3
Weighted average exercise price $73.77 $66.27 
Aggregate intrinsic value (in millions)
$825 $825 

The total unrecognized share-based compensation cost at September 30, 2023 amounted to approximately $560 million which is expected to be recognized over the next three years.

15
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 10 — Debt and Lines of Credit

On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity. The repayment equated to approximately $1.2 billion. In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition. On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.3 billion at September 30, 2023 and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2023 and December 31, 2022, Abbott held the gross notional amounts of $14.2 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $401 million and $446 million as of September 30, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at September 30, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

16
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2023 and December 31, 2022:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30,
2023		December 31, 2022Balance Sheet CaptionSeptember 30,
2023		December 31, 2022Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$— $— Deferred income taxes and other assets$158 $136 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables13 20 Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments254 304 Prepaid expenses and other receivables63 96 Other accrued liabilities
Others not designated as hedges113 108 Prepaid expenses and other receivables115 130 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a401 446 Long-term debt
$367 $412 $750 $828 

17
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2023 and 2022.

Gain (loss) Recognized in Other
Comprehensive Income (loss)		Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023202220232022Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$125 $350 $152 $442 $22 $79 $211 $149 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary12 24 45 108 n/an/an/an/an/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(18)(85)(15)(253)Interest expense

A gain of $60 million and a loss of $27 million were recognized in the three months ended September 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A loss of $4 million and a gain of $225 million were recognized in the first nine months ended September 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2023December 31, 2022
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$566 $566 $558 $558 
Other222 222 208 208 
Total Long-term Debt(15,528)(14,681)(16,773)(16,313)
Foreign Currency Forward Exchange Contracts:   
Receivable position367 367 412 412 
(Payable) position(178)(178)(226)(226)
Interest Rate Hedge Contracts:    
Receivable position— — — — 
(Payable) position(171)(171)(156)(156)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
18
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
September 30, 2023:
Equity securities$304 $304 $— $— 
Foreign currency forward exchange contracts367 — 367 — 
Total Assets$671 $304 $367 $— 
Fair value of hedged long-term debt$2,702 $— $2,702 $— 
Interest rate swap derivative financial instruments171 — 171 — 
Foreign currency forward exchange contracts178 — 178 — 
Contingent consideration related to business combinations109 — — 109 
Total Liabilities$3,160 $— $3,051 $109 
December 31, 2022:
Equity securities$307 $307 $— $— 
Foreign currency forward exchange contracts412 — 412 — 
Total Assets$719 $307 $412 $— 
Fair value of hedged long-term debt$2,691 $— $2,691 $— 
Interest rate swap derivative financial instruments156 156 
Foreign currency forward exchange contracts226 — 226 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,203 $— $3,073 $130 

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2022 reflects the impact of projected timeline changes for events that will trigger payment of contingent consideration, partially offset by additional contingent consideration due to a recent business acquisition.

19
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)

Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $25 million to $35 million. The recorded accrual balance at September 30, 2023 for these proceedings and exposures was approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023202220232022
Service cost - benefits earned during the period$56 $92 $174 $282 $10 $13 $29 $38 
Interest cost on projected benefit obligations114 74 342 225 15 9 45 27 
Expected return on plan assets(244)(231)(729)(701)(6)(8)(18)(23)
Curtailment gain— — (14)— — — — — 
Net amortization of:
Actuarial loss, net2 58 8 174 (1)2 (2)8 
Prior service cost (credit)1 — 1 1 (3)(6)(10)(18)
Net cost (credit)$(71)$(7)$(218)$(19)$15 $10 $44 $32 

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2023 and 2022, $302 million and $362 million, respectively, were contributed to defined benefit plans. In the first nine months of 2023 and 2022, $28 million was contributed, in each year, to the post-employment medical and dental plans.

20
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2023 and 2022, taxes on earnings include approximately $11 million and $36 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2023 and 2022, taxes on earnings also include approximately $59 million and $20 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $55 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott expects to file a petition with the U.S. Tax Court contesting the 2019 SNOD in December of 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15% minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have indicated their intent to adopt the proposal and are drafting legislation to implement the Pillar 2 model rules with a subset of the rules becoming effective January 1, 2024, and the remaining rules becoming effective January 1, 2025, or in later periods. Abbott is also continuing to analyze the Pillar 2 model rules. Implementation of the OECD proposal may have a material impact on Abbott’s Condensed Consolidated Financial Statements in the future.


21
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)

Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

22
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2023
(Unaudited)
Note 15 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023 2022 2023 2022
Established Pharmaceutical Products$1,368 $1,326 $3,844 $3,696 $345 $331 $952 $831 
Nutritional Products2,073 1,795 6,116 5,642 284 69 972 550 
Diagnostic Products2,449 3,641 7,454 13,192 632 1,346 1,720 5,615 
Medical Devices4,249 3,645 12,444 11,024 1,342 1,045 3,805 3,288 
Total Reportable Segments10,139 10,407 29,858 33,554 2,603 2,791 7,449 10,284 
Other 4 3 10 8 
Net sales$10,143 $10,410 $29,868 $33,562 
Corporate functions and benefit plan costs(50)(115)(198)(352)
Net interest expense (69)(86)(182)(309)
Share-based compensation (a) (117)(123)(530)(570)
Amortization of intangible assets(496)(498)(1,485)(1,517)
Other, net (b)(200)(211)(185)(550)
Earnings before taxes$1,671 $1,758 $4,869 $6,986 
______________________________________
Notes:Three and nine months ended September 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI and charges related to restructuring actions and intangible asset and investment impairments. Other, net for the nine months ended September 30, 2023 also includes income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment, $111 million of charges related to the impairment of IPR&D intangible assets as well as integration costs related to the acquisition of Alere Inc. and restructuring charges.
23
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review — Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.
Net Sales to External Customers
(in millions)Three Months Ended
September 30, 2023		Three Months Ended
September 30, 2022		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$1,368 $1,326 3.2 %(7.9)%11.1 %
Nutritional Products2,073 1,795 15.5 (1.4)16.9 
Diagnostic Products2,449 3,641 (32.7)(0.8)(31.9)
Medical Devices4,249 3,645 16.6 0.6 16.0 
Total Reportable Segments10,139 10,407 (2.6)(1.4)(1.2)
Other4 3 n/mn/mn/m
Net Sales$10,143 $10,410 (2.6)(1.4)(1.2)
Total U.S.$3,817 $4,094 (6.8)— (6.8)
Total International$6,326 $6,316 0.2 (2.2)2.4 
Net Sales to External Customers
(in millions)Nine Months Ended
September 30, 2023		Nine Months Ended
September 30, 2022		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$3,844 $3,696 4.0 %(7.6)%11.6 %
Nutritional Products6,116 5,642 8.4 (2.8)11.2 
Diagnostic Products7,454 13,192 (43.5)(1.4)(42.1)
Medical Devices12,444 11,024 12.9 (1.7)14.6 
Total Reportable Segments29,858 33,554 (11.0)(2.4)(8.6)
Other10 8 n/mn/mn/m
Net Sales$29,868 $33,562 (11.0)(2.4)(8.6)
Total U.S.$11,503 $13,923 (17.4)— (17.4)
Total International$18,365 $19,639 (6.5)(4.1)(2.4)
______________________________________
Notes:The Acelis Connected Health business was internally transferred from Diagnostic Products to Medical Devices on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Diagnostic Products to Medical Devices.
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
24
The 1.2 percent decrease in total net sales during the third quarter of 2023, excluding the impact of foreign exchange, reflected the decrease in demand for Abbott’s rapid diagnostic tests to detect COVID-19, partially offset by higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $305 million during the third quarter of 2023 and approximately $1.7 billion during the third quarter of 2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 12.6 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 14.1 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the third quarter as the relatively stronger U.S. dollar decreased total international sales by 2.2 percent and total sales by 1.4 percent.

The 8.6 percent decrease in total net sales during the first nine months of 2023, excluding the impact of foreign exchange, reflected lower demand for Abbott’s COVID-19 tests, partially offset by higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $1.3 billion during the first nine months of 2023 and approximately $7.3 billion during the first nine months of 2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 8.8 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 11.8 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first nine months as the relatively stronger U.S. dollar decreased total international sales by 4.1 percent and total sales by 2.4 percent.

Due to the unpredictability of demand for COVID-19 tests, the future extent to which COVID-19 will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.

The table below provides detail by sales category for the nine months ended September 30, 2023. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)September 30,
2023		September 30,
2022		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets$2,889 $2,853 1.3 %(8.7)%10.0 %
Other Emerging Markets955 843 13.2 (3.9)17.1 
Nutritionals —
International Pediatric Nutritionals1,477 1,491 (0.9)(3.8)2.9 
U.S. Pediatric Nutritionals1,472 1,108 32.8 — 32.8 
International Adult Nutritionals2,086 2,027 2.9 (5.0)7.9 
U.S. Adult Nutritionals1,081 1,016 6.4 — 6.4 
Diagnostics —
Core Laboratory3,789 3,624 4.6 (3.5)8.1 
Molecular421 815 (48.4)(0.9)(47.5)
Point of Care416 394 5.5 (0.4)5.9 
Rapid Diagnostics2,828 8,359 (66.2)(0.6)(65.6)
Medical Devices —
Rhythm Management1,673 1,605 4.3 (1.7)6.0 
Electrophysiology1,602 1,440 11.3 (2.8)14.1 
Heart Failure860 777 10.7 (0.2)10.9 
Vascular2,004 1,878 6.7 (2.1)8.8 
Structural Heart1,446 1,271 13.8 (1.5)15.3 
Neuromodulation650 568 14.4 (1.1)15.5 
Diabetes Care4,209 3,485 20.8 (1.5)22.3 
Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $87 million of sales for the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.
25
Excluding the unfavorable effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 10.0 percent in the first nine months of 2023, led by growth in several countries and across several therapeutic areas, including cardiometabolic, women's health, and central nervous system/pain management. Other Emerging Markets, excluding the effect of foreign exchange, increased by 17.1 percent in the first nine months of 2023.

Excluding the impact of foreign exchange, total Nutritional Products sales in the first nine months of 2023 increased 11.2 percent. The 32.8 percent increase in U.S. Pediatric Nutritional sales in the first nine months of 2023 reflects progress in recovering market share in 2023 following the voluntary recall of certain infant formula products in the first quarter of 2022, as well as the unfavorable 2022 impact of the recall, partially offset by a decrease in 2023 Pedialyte® sales. Excluding the effect of foreign exchange, the 2.9 percent increase in International Pediatric Nutritional sales in the first nine months of 2023 primarily reflects growth in various markets, partially offset by the impact of exiting the pediatric nutrition business in China. The increases of 6.4 percent in U.S. Adult Nutritionals and 7.9 percent, excluding the effect of foreign exchange, in International Adult Nutritionals in the first nine months of 2023 were led by growth of Ensure® and Glucerna® products.

The 42.1 percent decrease in Diagnostic Products sales in the first nine months of 2023, excluding the impact of foreign exchange, was driven by lower demand for COVID-19 tests. In Rapid Diagnostics, sales decreased 65.6 percent in the first nine months of 2023, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first nine months of 2023 and 2022, Rapid Diagnostics COVID-19 testing-related sales were $1.2 billion and $6.9 billion, respectively. In the first nine months of 2023, Rapid Diagnostics sales increased 6.5 percent, excluding COVID-19 testing-related sales, and increased 8.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Core Laboratory Diagnostics, sales increased 8.1 percent in the first nine months of 2023, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing performed in hospitals and other laboratories, partially offset by lower test sales for the detection of COVID-19 IgG and IgM antibodies. In the first nine months of 2023 and 2022, Core Laboratory Diagnostics COVID-19 testing-related sales were $16 million and $51 million, respectively. In the first nine months of 2023, Core Laboratory Diagnostics sales increased 5.6 percent, excluding COVID-19 testing-related sales, and increased 9.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales. In the third quarter of 2023, Core Laboratory Diagnostics received U.S. Food and Drug Administration (FDA) clearance for its Alinity® h-series hematology system, which integrates hematology workflow from high-throughput Complete Blood Count analysis to automated slide making and staining.

The 47.5 percent decrease in Molecular Diagnostics sales in the first nine months of 2023, excluding the effect of foreign exchange, was driven by lower demand for laboratory-based molecular tests for COVID-19, as well as lower demand for respiratory testing compared to significantly higher-than-usual demand in the first nine months of 2022. In the first nine months of 2023 and 2022, Molecular Diagnostics COVID-19 testing-related sales were $36 million and $375 million, respectively. In the first nine months of 2023, Molecular Diagnostics sales decreased 12.8 percent, excluding COVID-19 testing-related sales, and decreased 11.3 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

Excluding the effect of foreign exchange, total Medical Devices sales grew 14.6 percent in the first nine months of 2023, led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure, Neuromodulation and Electrophysiology. Higher Diabetes Care sales were driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $3.9 billion in the first nine months of 2023, which reflected a 26.2 percent increase, excluding the effect of foreign exchange, over the first nine months of 2022 when FreeStyle Libre sales totaled $3.1 billion.

During the first nine months of 2023, procedure volumes increased across the cardiovascular and neuromodulation businesses. In Structural Heart, the 15.3 percent increase in sales, excluding the effect of foreign exchange, reflects continued growth of the MitraClip® product along with contributions from various products, including Amulet®, Navitor®, and TriClip®. In Vascular, the 8.8 percent increase in sales, excluding the impact of foreign exchange, during the first nine months of 2023 reflects the acquisition of Cardiovascular Systems, Inc. (CSI) on April 27, 2023, as well as double-digit growth in endovascular sales.

In Electrophysiology, the 14.1 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher procedure volumes in the U.S., China, and various European countries. In Neuromodulation, the 15.5 percent increase in sales, excluding the effect of foreign exchange, was driven by the recent launch of the Eterna® rechargeable spinal cord stimulation system for the treatment of chronic pain along with market growth compared to the prior year period.
26
In the first nine months of 2023, Medical Devices received various product approvals. In January 2023, Abbott announced that the U.S. FDA had approved Navitor, Abbott's second-generation transcatheter aortic valve implantation system to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. In March 2023, Abbott's Freestyle Libre continuous glucose monitoring system received U.S. FDA clearance for integration with automated insulin delivery systems. In March 2023, the U.S. FDA approved Abbott's Epic® Max stented tissue valve to treat people with aortic regurgitation or stenosis. In May 2023, Abbott received U.S. FDA approval of its TactiFlex® Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a flexible electrode tip and contact force sensing technology to treat patients with atrial fibrillation. In June 2023, Abbott received U.S. FDA approval of its AVEIR™ dual chamber leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. In July 2023, Abbott obtained CE Mark for its AVEIR single-chamber leadless pacemaker.

The gross profit margin percentage was 49.7 percent for the third quarter of 2023 compared to 50.7 percent for the third quarter of 2022 and 50.1 percent for the first nine months of 2023 compared to 52.1 percent for the first nine months of 2022. The decrease in the third quarter and first nine months of 2023 reflects the unfavorable effects of lower sales of COVID-19 tests, foreign exchange, and higher costs for various manufacturing inputs, partially offset by the impact in 2022 of the voluntary product recall in the Nutritional business and the impact in 2023 of gross margin improvement initiatives.

Research and development (R&D) expenses decreased $110 million, or 14.0 percent, in the third quarter of 2023 and decreased $122 million, or 5.6 percent, in the first nine months of 2023 compared to the prior year. The decrease in R&D expense in the third quarter and first nine months of 2023 was primarily driven by the non-recurrence of an impairment charge recognized in 2022 related to in-process R&D assets acquired in a previous business combination.

Selling, general and administrative expenses decreased $8 million, or 0.3 percent, in the third quarter of 2023, and decreased $50 million, or 0.6 percent, in the first nine months of 2023 compared to the prior year. Higher selling and marketing spending to drive growth across various businesses was offset by the favorable impact of foreign exchange. The decrease during the first nine months of 2023 also reflects the non-recurrence of 2022 expenses related to the voluntary product recall in the Nutritional segment.

Interest Expense, net

Interest expense, net decreased from $86 million in the third quarter of 2022 to $69 million in the third quarter of 2023 and decreased from $309 million in the first nine months of 2022 to $182 million in the first nine months of 2023. The decreases were due to the favorable impact of higher interest rates on interest income, partially offset by the negative impact of interest rate hedge contracts related to certain fixed-rate debt.

Other (Income) Expense, net

Other income, net decreased from $93 million of income in the third quarter of 2022 to $83 million of income in the third quarter of 2023 and increased from $253 million of income in the first nine months of 2022 to $370 million of income in the first nine months of 2023. The third quarter and the first nine months of 2023 reflect higher income in 2023 related to the non-service cost components of net pension and post-retirement medical benefit costs. In the third quarter of 2023, the decline in Other income, net is due to higher impairment charges related to long term investments that more than offset the increase in income associated with the non-service component of pension and post-retirement medical plans.

Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2023 and 2022, taxes on earnings include approximately $11 million and $36 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2023 and 2022, taxes on earnings also include approximately $59 million and $20 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $55 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

27
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott expects to file a petition with the U.S. Tax Court contesting the 2019 SNOD in December of 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15% minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have indicated their intent to adopt the proposal and are drafting legislation to implement the Pillar 2 model rules with a subset of the rules becoming effective January 1, 2024, and the remaining rules becoming effective January 1, 2025, or in later periods. Abbott is also continuing to analyze the Pillar 2 model rules. Implementation of the OECD proposal may have a material impact on Abbott’s Condensed Consolidated Financial Statements in the future.

Liquidity and Capital Resources September 30, 2023 Compared with December 31, 2022

The decrease in cash and cash equivalents from $9.9 billion at December 31, 2022 to $6.7 billion at September 30, 2023 primarily reflects the payment of dividends, the repayment of debt, share repurchases, the cost of business acquisitions and capital expenditures, partially offset by the cash generated from operations in the first nine months of 2023. Working capital was $9.6 billion at September 30, 2023 and $9.7 billion at December 31, 2022. The decrease in working capital in 2023 primarily reflects a decrease in cash and cash equivalents, which was nearly offset by increases in accounts receivables and inventory and decreases in the current portion of long-term debt, accounts payable and other accrued liabilities.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of 2023 totaled approximately $4.2 billion, a decrease of $3.0 billion from the prior year. The decrease is primarily due to the decline in operating earnings and an increase in cash taxes paid. Net cash from operating activities in 2023 includes $302 million of pension contributions and the payment of cash taxes of approximately $1.180 billion. Net cash from operating activities in 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million.

On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity. The repayment equated to approximately $1.2 billion. In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition. On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of September 30, 2023, $2.15 billion of the $5 billion authorization remains available.

At September 30, 2023, Abbott’s long-term debt rating was AA- by S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.

28
In the first nine months of 2023, Abbott repurchased approximately 7 million of its common shares for $725 million. As of September 30, 2023, $1.709 billion remains available for repurchase under the share repurchase program authorized by the board of directors in December 2021.

In each of the first three quarters of 2023, Abbott declared a quarterly dividend of $0.51 per share on its common shares, which represents an increase of 8.5 percent over the $0.47 per share dividend declared in each of the first three quarters of 2022.

Business Acquisitions

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management even more personal and precise. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of CSI for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

The preliminary allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets of $305 million; non-deductible in-process research and development of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $384 million; net deferred tax assets of approximately $31 million and other net assets of approximately $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.


Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2022 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
29
PART I. FINANCIAL INFORMATION

Item 4.     Controls and Procedures

(a)Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Philip P. Boudreau, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)Changes in internal control over financial reporting. During the quarter ended September 30, 2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.     Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

Period(a) Total
Number of
Shares (or
Units)
Purchased		(b) Average
Price Paid per
Share (or
Unit)		(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs		(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
July 1, 2023 - July 31, 2023—
(1)
$— —$1,709,092,863 
(2)
August 1, 2023 - August 31, 2023—
(1)
——1,709,092,863 
(2)
September 1, 2023 - September 30, 2023—
(1)
——1,709,092,863 
(2)
Total—
(1)
——$1,709,092,863 
(2)
______________________________________
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.
30
Item 6.     Exhibits
Exhibit No.Exhibit
31.1
31.2
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1
32.2
101The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).
31
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By:/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Senior Vice President, Finance
and Chief Financial Officer
Date: November 1, 2023
32
 EX-31.1 2 q3202310qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: November 1, 2023/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer

 EX-31.2 3 q3202310qex312.htm EX-31.2 Document

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Philip P. Boudreau, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: November 1, 2023/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Senior Vice President, Finance
and Chief Financial Officer

 EX-32.1 4 q3202310qex321.htm EX-32.1 Document

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
November 1, 2023
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 5 q3202310qex322.htm EX-32.2 Document

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Philip P. Boudreau, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Senior Vice President, Finance
and Chief Financial Officer
November 1, 2023
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 6 abt-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Incentive Stock Programs link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Debt and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - New Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Incentive Stock Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Supplemental Financial Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Supplemental Financial Information - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Restructuring Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Restructuring Plans - Restructuring Activity and Related Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Incentive Stock Programs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Incentive Stock Programs - Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Debt and Lines of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Post-Employment Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 abt-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 abt-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 abt-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Award Type [Domain] Award Type [Domain] Expected timing of satisfaction period (in months) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Prepaid expenses and other receivables Prepaid Expense and Other Receivables [Member] The Other Prepaid Expenses and Receivables line item in the statement of financial position in which the amounts are included. Debt and Lines of Credit Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Neuromodulation Neuromodulation [Member] It represents the neuromodulation, segment of the entity. Acquisitions of businesses and technologies, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets. Net actuarial (losses) and prior service (costs) and credits Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Segment Reporting [Abstract] Segment Reporting [Abstract] Exercisable options, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Pediatric Nutritionals Pediatric Nutritionals [Member] It represents the pediatric nutritionals, segment of the entity. Commitments and Contingencies Commitments and Contingencies Impairment of indefinite-lived intangible assets Impairment of IPR&D intangible assets Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Exercisable options, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Curtailment gain Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations. Geographical [Axis] Geographical [Axis] Taxes on Earnings Income Tax Disclosure [Text Block] Current Liabilities: Liabilities, Current [Abstract] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Investments in mutual funds held in a rabbi trust Common Stock, Shares Held in Employee Trust Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Inventories: Inventory, Net [Abstract] Dividends paid Payments of Ordinary Dividends, Common Stock Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted Earnings Per Common Share (in dollars per share) Earnings Per Share, Diluted Yen-denominated term loan Fair Value - Liabilities (Payable) position Derivative Liability, Subject to Master Netting Arrangement, before Offset Hedging Relationship [Axis] Hedging Relationship [Axis] Trade receivables, less allowances of $472 in 2023 and $500 in 2022 Accounts Receivable, after Allowance for Credit Loss, Current Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent [Member] The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included. Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 and $(24) in 2023 and $50 and $96 in 2022 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Acquisition share price (in dollars per share) Business Acquisition, Share Price Significant Unobservable Inputs Fair Value, Inputs, Level 3 [Member] Common shares held in treasury (in shares) Beginning balance, treasury stock, common (in shares) Ending balance, treasury stock, common (in shares) Treasury Stock, Common, Shares Condensed Cash Flow Statement [Table] Condensed Cash Flow Statement [Table] Molecular Molecular [Member] It represents the molecular, segment of the entity. Stock options outstanding, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Net Periodic Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Trading Symbol Trading Symbol Five Year Term Loan due 2024 Five Year Term Loan due 2024 [Member] Five Year Term Loan due 2024 Restructuring Plan [Domain] Restructuring Plan [Domain] Net Earnings Net Earnings Net earnings Net Income (Loss) Total Current Liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Liabilities and Shareholders’ Investment Liabilities and Equity [Abstract] 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses [Member] The entity's 2022 and 2023 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. Sales (purchases) of other investment securities, net Payments for (Proceeds from) Investments Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Cost of products sold Cost of Goods and Services Sold [Member] Cost of Goods and Services Sold Beginning balance Ending balance Contract with Customer, Liability Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Cost of products sold, excluding amortization of intangible assets Cost of Goods and Services Sold Service cost - benefits earned during the period Defined Benefit Plan, Service Cost Inventory recall expense Inventory Recall Expense Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Quoted Prices in Active Markets Fair Value, Inputs, Level 1 [Member] Debt Debt [Member] Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(1) and $(4) in 2023 and $11 and $36 in 2022 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Carrying Value Reported Value Measurement [Member] Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Incentive stock program, shares reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Investment Type [Axis] Investment Type [Axis] Measurement Basis [Axis] Measurement Basis [Axis] Stock options granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Estimated annual amortization expense, intangible assets, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Investments [Domain] Investments [Domain] Changes In Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Trade receivables Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Tax expense from prior year tax positions Tax Adjustments, Settlements, and Unusual Provisions Derivative, notional amount Derivative, Notional Amount Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Cash dividends declared on common shares (in dollars per share) Common Stock, Dividends, Per Share, Declared Measurement Frequency [Axis] Measurement Frequency [Axis] Prepaid expenses and other receivables, current Prepaid Expenses and Other Receivables, Current [Member] Prepaid Expenses and Other Receivables, Current Retirement Plan Type [Domain] Retirement Plan Type [Domain] Diabetes Care Diabetes Care [Member] It represents the Diabetes Care, segment of the entity. Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Debt instrument, term Debt Instrument, Term Effect of common and treasury share transactions Effect of Common and Treasury Share Transactions This element represents the effect on retained earning due to common and treasury stock transactions. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] St. Jude Medical St Jude Medical [Member] Represents information relating to acquisition of St. Jude Medical, Inc. Income Statement Location [Axis] Income Statement Location [Axis] Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Foreign Currency Forward Exchange Contracts Foreign Exchange Forward [Member] Structural Heart Structural Heart [Member] It represents the structural heart, segment of the entity. Heart Failure Heart Failure [Member] It represents the Heart Failure, segment of the entity. Income taxes payable Accrued Income Taxes, Current Schedule of Carrying Values and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Rhythm Management Rhythm Management [Member] It represents the rhythm management, segment of the entity. Increase in in-process R&D due to acquisition Indefinite-Lived Intangible Assets, Period Increase (Decrease) Inventories Increase (Decrease) in Inventories Research and Development Research and Development Expense [Member] Cash Flow From (Used in) Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accrued balance at beginning of the period Accrued balance at end of the period Restructuring Reserve Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Outstanding Common Stock Options Having No Dilutive Effect (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted stock awards granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Property and equipment, at cost Property, Plant and Equipment, Gross Stock options outstanding, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Key Emerging Markets Key Emerging Markets [Member] It represents the key emerging markets, segment of the entity. Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Estimated annual amortization expense, intangible assets, 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Issued under incentive stock programs Stock Issued During Period, Value, Incentive Stock Programs Stock Issued During Period, Value, Incentive Stock Programs Pension contributions Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Investments Total Long-term Investment Securities: Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and Cash Equivalents, Beginning of Year Cash and Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization of intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Prepaid expenses and other receivables Prepaid Expense and Other Receivables Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer. Interest (income) Investment Income, Interest Common shares, issued (in shares) Common Stock, Shares, Issued Acquisition purchase price Business Combination, Consideration Transferred Restructuring charges Restructuring charges in 2023 Severance Costs Common shares held in treasury, at cost — Shares: 2023: 251,246,618; 2022: 248,724,257 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total Assets Assets, Fair Value Disclosure Total Long-term Debt Long-Term Debt Number of developed technology intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive income (loss) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Stock Options Employee Stock Option [Member] Cumulative Foreign Currency Translation (Loss) Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Interest rate swap derivative financial instruments Interest Rate Derivative Liabilities, at Fair Value Total unrecognized compensation cost, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating cost and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Entity Address, Address Line One Entity Address, Address Line One Purchased Treasury Stock, Value, Acquired, Cost Method Increase in amortizable intangible assets due to acquisition Finite-Lived Intangible Assets, Period Increase (Decrease) Incentive Stock Programs Share-Based Payment Arrangement [Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Trade receivables, allowances Accounts Receivable, Allowance for Credit Loss, Current Derivative [Table] Derivative [Table] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Income Statement [Abstract] Income Statement [Abstract] Materials Inventory, Raw Materials, Net of Reserves Issued under incentive stock programs (in shares) Stock Issued During Period, Shares, Incentive Stock Programs Stock Issued During Period, Shares, Incentive Stock Programs Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Point of Care Point of Care [Member] It represents the point of care, segment of the entity. Restructuring Activity and Related Accruals Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Business Acquisitions Business Combination Disclosure [Text Block] Indefinite-lived intangible assets related to in-process R&D acquired in a business combination Indefinite-Lived Intangible Assets (Excluding Goodwill) Operating Segments Operating Segments [Member] Share-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Dividends payable Dividends Payable, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Decrease in goodwill due to foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Equity method investments carrying value Equity Method Investments Total inventories Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Other Other Investments [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Purchases of common shares Payments for Repurchase of Common Stock Corporate functions and benefit plan costs Corporate and Benefit Plan Costs The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Restricted Stock Awards Restricted stock awards [Member] Restricted stock awards. Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consolidation Items [Domain] Consolidation Items [Domain] Earnings employed in the business Retained Earnings (Accumulated Deficit) Payment of cash taxes Payments for Other Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current Assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Cash Flow From (Used in) Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Diagnostics Diagnostic Products Diagnostic Products [Member] The diagnostics products segment of the entity. Estimated annual amortization expense, intangible assets, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Interest cost on projected benefit obligations Defined Benefit Plan, Interest Cost Estimation of possible loss Loss Contingency, Estimate of Possible Loss Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Fair Value - Assets Receivable position Derivative Asset, Subject to Master Netting Arrangement, before Offset Foreign currency translation gain (loss) adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net Cash From (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Equity securities Equity Securities, FV-NI, Current Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Net earnings allocated to common shares Net Income (Loss) Available to Common Stockholders, Basic Interest Rate Hedge Contracts Interest Rate Swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Increase in goodwill due to acquisition Goodwill, Period Increase (Decrease) Repayments of debt Repayments of Debt Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold Minimum Length Of Time Hedged In Cash Flow Hedge Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Net Actuarial (Losses) and Prior Service (Costs) and Credits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Number of reportable segments Number of Reportable Segments Decrease reasonably possible in gross unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,305,154; 2022: 1,986,519,278 Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total Current Assets Assets, Current Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Medical Devices Medical Devices [Member] The medical devices segment of the entity. Net cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Contingent consideration related to business combinations Business Combination, Contingent Consideration, Liability Equity securities Equity Securities [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Statement [Table] Statement [Table] Other, net Other Cost and Expense, Operating and Nonoperating The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses. Subsegments [Domain] Subsegments [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Trade accounts payable Accounts Payable, Trade, Current Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred shares, authorized (in shares) Preferred Stock, Shares Authorized Medical and Dental Plans Other Postretirement Benefits Plan [Member] Net Cash From Operating Activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Excess tax benefits associated with share-based compensation Excess Tax Benefit from Share-based Compensation Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Other accrued liabilities Other Accrued Liabilities, Current Prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Other Corporate, Non-Segment [Member] Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Unearned revenue from cash received during the period Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized Amount of revenue recognized arising from contract liability from change in cash received to be satisfied. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Net deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Business Combination and Asset Acquisition [Abstract] Total Abbott Shareholders’ Investment Beginning of the period End of the period Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Amount of reductions of goodwill relating to impairments Goodwill, Impairment Loss Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognized related to contract liability balance Contract with Customer, Liability, Revenue Recognized Subsegments [Axis] Subsegments [Axis] Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Earnings before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Equity investments without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Fixed asset impairment charges Tangible Asset Impairment Charges Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Preferred shares, issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Significant Other Observable Inputs Fair Value, Inputs, Level 2 [Member] Other Other Security Investments [Member] Net Investment Hedging Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Intangible assets, net of amortization Intangible Assets, Net (Excluding Goodwill) Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Shareholders' Investment Increase (Decrease) in Stockholders' Equity [Roll Forward] Developed technology intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Stock options outstanding, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Common Shares Common Stock [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total Shareholders’ Investment Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Net property and equipment Property, Plant and Equipment, Net Summary of Options Outstanding and Exercisable Share-Based Payment Arrangement, Option, Activity [Table Text Block] Gain (loss) from foreign currency forward exchange contracts not designated as hedges Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash dividends declared on common shares Dividends, Common Stock, Cash Assets Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Total Liabilities Liabilities, Fair Value Disclosure Summary of Amounts and Location of Derivative Financial Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net foreign exchange (gain) loss Gain (Loss), Foreign Currency Transaction, before Tax Net Cash From (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Other Payments for (Proceeds from) Other Investing Activities Earnings Employed in the Business Retained Earnings [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Total Liabilities and Shareholders' Investment Liabilities and Equity Other net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Basic Earnings Per Common Share (in dollars per share) Earnings Per Share, Basic Core Laboratory Core Laboratory [Member] It represents the core laboratory, segment of the entity. Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Percentage of remaining performance obligation expected to be recognized in period Revenue Remaining Performance Obligation Expected Timing Percentage Represents the percentage of revenue recognized for remaining performance obligations. Schedule of Long-term Investments Schedule of Long Term Investments [Table Text Block] Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle). Entity Address, City or Town Entity Address, City or Town Established Pharmaceutical Products Established Pharmaceutical Products [Member] Represents Established Pharmaceutical Products, segment of the entity. Schedule of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Disclosure Text Block Supplement [Abstract] Disclosure Text Block Supplement [Abstract] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets Document Transition Report Document Transition Report Interest expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Proceeds from business dispositions Proceeds from Sales of Business, Affiliate and Productive Assets Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Common shares, authorized (in shares) Common Stock, Shares Authorized 2.55% Long-term Notes Due 2022 2.55% Long-term Notes Due 2022 [Member] 2.55% Long-term Notes Due 2022 Fair value of hedged long-term debt Hedged Liability, Fair Value Hedge Document Information [Table] Document Information [Table] Summary of Investment Holdings [Line Items] Summary of Investment Holdings [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net earnings to net cash from operating activities — Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Nutritionals Nutritional Products Nutritional Products [Member] The nutritional products segment of the entity. Derivative [Line Items] Derivative [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Rapid Diagnostics Rapid Diagnostics [Member] It represents the rapid diagnostics, segment of the entity. Provisions/charges to income Accounts Receivable, Credit Loss Expense (Reversal) Document and Entity Information Document Information [Line Items] Restructuring Plan [Axis] Restructuring Plan [Axis] Proceeds from stock options exercised Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Bigfoot Bigfoot Biomedical [Member] Bigfoot Biomedical Decrease in intangible assets due to foreign currency translation adjustments Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Estimated annual amortization expense, intangible assets, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Changes in accumulated other comprehensive income (loss), net of income taxes AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Vascular Vascular [Member] It represents the vascular products, segment of the entity. Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name Contract Liabilities: Contract Liabilities [Roll Forward] Contract Liabilities Dilutive Common Stock Options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Estimated annual amortization expense, intangible assets, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Condensed Cash Flow Statements, Captions [Line Items] Condensed Cash Flow Statements, Captions [Line Items] Electrophysiology Electrophysiology [Member] It represents the electrophysiology, segment of the entity. Exchange [Domain] Exchange [Domain] Noncontrolling Interests in Subsidiaries Equity, Attributable to Noncontrolling Interest Net borrowings (repayments) of short-term debt and other Proceeds from (Repayments of) Short-Term Debt Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Issuance of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable options, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net amortization of: Defined Benefit Plan Net Amortization Costs [Abstract] No definition available. Repayments of long-term debt Repayments of Long-Term Debt Summary of Allowance for Doubtful Accounts Activity Accounts Receivable, Allowance for Credit Loss [Table Text Block] Common Shares Held in Treasury Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Recorded accrual balance for legal proceedings and exposures Loss Contingency Accrual Liabilities, at Fair Value Liabilities, Fair Value Disclosure [Abstract] 0.875% Long-term Notes Due 2023 0.875% Long-term Notes Due 2023 [Member] 0.875% Long-term Notes Due 2023 Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Annual share-based awards recognized in first quarter (as a percent) Annual Share Based Awards Recognized in First Quarter Percent Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter. Share-based compensation Share-Based Payment Arrangement, Expense Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Gross amount of amortizable intangible assets Finite-Lived Intangible Assets, Gross Taxes on earnings Income Tax Expense (Benefit) International Non-US [Member] Finished products Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument Designated as Hedging Instrument [Member] Amounts charged off and other deductions Accounts Receivable, Allowance for Credit Loss, Writeoff Salaries, wages and commissions Employee-related Liabilities, Current Maximum expected cleanup exposure in aggregate Loss Contingency Range of Possible Loss, Maximum Aggregate Sites The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico. Other accrued liabilities Other Accrued Liabilities, Current [Member] Other Accrued Liabilities, Current Amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Summary of Revenue by Sales Category Disaggregation of Revenue [Table Text Block] Net sales Net Sales to External Customers Revenue from Contract with Customer, Excluding Assessed Tax CSI Cardiovascular Systems, Inc. [Member] Cardiovascular Systems, Inc. Amendment Flag Amendment Flag In-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Fair Value Hedging Fair Value Hedging [Member] Actuarial loss, net Defined Benefit Plan, Amortization of Gain (Loss) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net interest expense Interest Income (Expense), Net Allowance for Doubtful Accounts: SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Legal proceedings and environmental exposures Legal proceedings and environmental exposures [Member] Loss contingencies related to legal proceedings and environmental exposures. Assets, at Fair Value Assets, Fair Value Disclosure [Abstract] Purchased (in shares) Treasury Stock, Shares, Acquired Long-term debt Long-Term Debt, Excluding Current Maturities Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities [Member] Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Schedule of Changes in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Revenue Revenue from Contract with Customer [Text Block] Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total Assets Assets Loss Contingencies [Line Items] Loss Contingencies [Line Items] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Adult Nutritionals Adult Nutritionals [Member] It represents the adult nutritionals, segment of the entity. Cover [Abstract] Cover [Abstract] Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax United States UNITED STATES Maximum expected cleanup exposure for individual site Loss Contingency Range of Possible Loss, Maximum Individual Site The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico. Outstanding Balances Fair Value, Recurring [Member] Segment Reconciling Items Segment Reconciling Items [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Long-term debt Long-Term Debt, Excluding Current Maturities [Member] Long-Term Debt, Excluding Current Maturities Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Short-term investments Short-Term Investments Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Cash Flow Hedging Cash Flow Hedging [Member] Defined Benefit Plans Pension Plan [Member] Segment Information Segment Reporting Disclosure [Text Block] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets Net Increase (Decrease) in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flow From (Used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component [Domain] Equity Component [Domain] Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer. Work in process Inventory, Work in Process, Net of Reserves Income tax claim related to statutory notice of deficiency IRS Statutory Notice of Deficiency, Claim Amount IRS Statutory Notice of Deficiency, Claim Amount Other Other Emerging Markets [Member] Other Emerging Markets Debt Instrument [Line Items] Debt Instrument [Line Items] Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating earnings Operating Earnings Operating Income (Loss) Segments [Axis] Segments [Axis] Statement Statement [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Summary of Investment Holdings [Table] Summary of Investment Holdings [Table] Shareholders’ Investment: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Noncontrolling Interests in Subsidiaries Noncontrolling Interest [Member] EX-101.PRE 10 abt-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
 9 Months Ended
Sep. 30, 2023
shares
Document and Entity Information  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Sep. 30, 2023
Document Transition Report false
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Incorporation, State or Country Code IL
Entity Tax Identification Number 36-0698440
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 1,736,058,536
Entity Central Index Key 0000001800
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2023
Document Fiscal Period Focus Q3
Amendment Flag false
NEW YORK STOCK EXCHANGE, INC.  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
CHICAGO STOCK EXCHANGE, INC  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Net sales $ 10,143 $ 10,410 $ 29,868 $ 33,562
Cost of products sold, excluding amortization of intangible assets 4,605 4,629 13,419 14,549
Amortization of intangible assets 496 498 1,485 1,517
Research and development 672 782 2,041 2,163
Selling, general and administrative 2,723 2,731 8,225 8,275
Total operating cost and expenses 8,496 8,640 25,170 26,504
Operating earnings 1,647 1,770 4,698 7,058
Interest expense 166 141 478 404
Interest (income) (97) (55) (296) (95)
Net foreign exchange (gain) loss (10) 19 17 16
Other (income) expense, net (83) (93) (370) (253)
Earnings before taxes 1,671 1,758 4,869 6,986
Taxes on earnings 235 323 740 1,086
Net Earnings $ 1,436 $ 1,435 $ 4,129 $ 5,900
Basic Earnings Per Common Share (in dollars per share) $ 0.82 $ 0.82 $ 2.36 $ 3.35
Diluted Earnings Per Common Share (in dollars per share) $ 0.82 $ 0.81 $ 2.35 $ 3.32
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) 1,738,700 1,752,968 1,740,255 1,756,209
Dilutive Common Stock Options (in shares) 9,589 10,685 9,819 11,638
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) 1,748,289 1,763,653 1,750,074 1,767,847
Outstanding Common Stock Options Having No Dilutive Effect (in shares) 7,334 5,445 5,474 2,655
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]          
Net Earnings $ 1,436 $ 1,435 $ 4,129 $ 5,900  
Foreign currency translation gain (loss) adjustments (480) (1,008) (393) (1,429)  
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(1) and $(4) in 2023 and $11 and $36 in 2022 (9) 56 (13) 172  
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 and $(24) in 2023 and $50 and $96 in 2022 80 213 (23) 186  
Other comprehensive income (loss) (409) (739) (429) (1,071)  
Comprehensive Income 1,027 $ 696 3,700 $ 4,829  
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:          
Cumulative foreign currency translation (loss) adjustments (7,126)   (7,126)   $ (6,733)
Net actuarial (losses) and prior service (costs) and credits (1,506)   (1,506)   (1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other 152   152   175
Accumulated other comprehensive income (loss) $ (8,480)   $ (8,480)   $ (8,051)
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit) $ (1) $ 11 $ (4) $ 36
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit) $ 30 $ 50 $ (24) $ 96
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current Assets:    
Cash and cash equivalents $ 6,709 $ 9,882
Short-term investments 338 288
Trade receivables, less allowances of $472 in 2023 and $500 in 2022 6,499 6,218
Inventories:    
Finished products 3,847 3,805
Work in process 888 680
Materials 1,915 1,688
Total inventories 6,650 6,173
Prepaid expenses and other receivables 2,468 2,663
Total Current Assets 22,664 25,224
Investments 788 766
Property and equipment, at cost 21,111 20,212
Less: accumulated depreciation and amortization 11,559 11,050
Net property and equipment 9,552 9,162
Intangible assets, net of amortization 9,282 10,454
Goodwill 23,277 22,799
Deferred income taxes and other assets 6,527 6,033
Total Assets 72,090 74,438
Current Liabilities:    
Trade accounts payable 3,961 4,607
Salaries, wages and commissions 1,479 1,556
Other accrued liabilities 5,347 5,845
Dividends payable 886 887
Income taxes payable 318 343
Current portion of long-term debt 1,051 2,251
Total Current Liabilities 13,042 15,489
Long-term debt 14,477 14,522
Post-employment obligations, deferred income taxes and other long-term liabilities 6,877 7,522
Commitments and Contingencies
Shareholders’ Investment:    
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 0 0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,305,154; 2022: 1,986,519,278 24,727 24,709
Common shares held in treasury, at cost — Shares: 2023: 251,246,618; 2022: 248,724,257 (15,686) (15,229)
Earnings employed in the business 36,920 35,257
Accumulated other comprehensive income (loss) (8,480) (8,051)
Total Abbott Shareholders’ Investment 37,481 36,686
Noncontrolling Interests in Subsidiaries 213 219
Total Shareholders’ Investment 37,694 36,905
Total Liabilities and Shareholders' Investment $ 72,090 $ 74,438
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Trade receivables, allowances $ 472 $ 500
Preferred shares, par value (in dollars per share) $ 1 $ 1
Preferred shares, authorized (in shares) 1,000,000 1,000,000
Preferred shares, issued (in shares) 0 0
Common shares, authorized (in shares) 2,400,000,000 2,400,000,000
Common shares, issued (in shares) 1,987,305,154 1,986,519,278
Common shares held in treasury (in shares) 251,246,618 248,724,257
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Increase (Decrease) in Shareholders' Investment        
Beginning balance     $ 36,905  
Net earnings $ 1,436 $ 1,435 4,129 $ 5,900
Other comprehensive income (loss) (409) (739) (429) (1,071)
Ending balance 37,694   37,694  
Common Shares        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 24,612 24,429 24,709 24,470
Issued under incentive stock programs 6 12 36 36
Share-based compensation 116 123 531 572
Issuance of restricted stock awards (7) (4) (549) (518)
Ending balance 24,727 24,560 24,727 24,560
Common Shares Held in Treasury        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (15,722) (13,720) (15,229) (11,822)
Issued under incentive stock programs 36 31 288 261
Purchased 0 (866) (745) (2,994)
Ending balance (15,686) (14,555) (15,686) (14,555)
Earnings Employed in the Business        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 36,355 34,487 35,257 31,528
Net earnings 1,436 1,435 4,129 5,900
Cash dividends declared on common shares (889) (822) (2,668) (2,475)
Effect of common and treasury share transactions 18 15 202 162
Ending balance 36,920 35,115 36,920 35,115
Accumulated Other Comprehensive Income (Loss)        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (8,071) (8,706) (8,051) (8,374)
Other comprehensive income (loss) (409) (739) (429) (1,071)
Ending balance (8,480) (9,445) (8,480) (9,445)
Noncontrolling Interests in Subsidiaries        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 230 226 219 222
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases (17) (17) (6) (13)
Ending balance $ 213 $ 209 $ 213 $ 209
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Increase (Decrease) in Shareholders' Investment        
Beginning balance, treasury stock, common (in shares)     248,724,257  
Ending balance, treasury stock, common (in shares) 251,246,618   251,246,618  
Common Shares        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (in shares) 1,987,181,491 1,985,676,735 1,986,519,278 1,985,273,421
Issued under incentive stock programs (in shares) 123,663 242,705 785,876 646,019
Ending balance (in shares) 1,987,305,154 1,985,919,440 1,987,305,154 1,985,919,440
Common Shares Held in Treasury        
Increase (Decrease) in Shareholders' Investment        
Beginning balance, treasury stock, common (in shares) 251,823,511 234,456,992 248,724,257 221,191,228
Issued under incentive stock programs (in shares) 579,159 528,436 4,669,629 4,808,575
Purchased (in shares) 2,266 8,417,107 7,191,990 25,963,010
Ending balance, treasury stock, common (in shares) 251,246,618 242,345,663 251,246,618 242,345,663
Earnings Employed in the Business        
Increase (Decrease) in Shareholders' Investment        
Cash dividends declared on common shares (in dollars per share) $ 0.51 $ 0.47 $ 1.53 $ 1.41
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flow From (Used in) Operating Activities:    
Net earnings $ 4,129 $ 5,900
Adjustments to reconcile net earnings to net cash from operating activities —    
Depreciation 945 943
Amortization of intangible assets 1,485 1,517
Share-based compensation 530 570
Trade receivables (424) (409)
Inventories (527) (1,224)
Other, net (1,915) (42)
Net Cash From Operating Activities 4,223 7,255
Cash Flow From (Used in) Investing Activities:    
Acquisitions of property and equipment (1,447) (1,167)
Acquisitions of businesses and technologies, net of cash acquired (877) 0
Proceeds from business dispositions 40 48
Sales (purchases) of other investment securities, net (45) (3)
Other 20 14
Net Cash From (Used in) Investing Activities (2,309) (1,108)
Cash Flow From (Used in) Financing Activities:    
Net borrowings (repayments) of short-term debt and other (90) 37
Proceeds from issuance of long-term debt 1 7
Repayments of long-term debt (1,447) (753)
Purchases of common shares (968) (3,110)
Proceeds from stock options exercised 133 126
Dividends paid (2,668) (2,486)
Net Cash From (Used in) Financing Activities (5,039) (6,179)
Effect of exchange rate changes on cash and cash equivalents (48) (173)
Net Increase (Decrease) in Cash and Cash Equivalents (3,173) (205)
Cash and Cash Equivalents, Beginning of Year 9,882 9,799
Cash and Cash Equivalents, End of Period $ 6,709 $ 9,594
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
New Accounting Standards
 9 Months Ended
Sep. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards
Note 2 — New Accounting Standards

Recently Adopted Accounting Standards
In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended September 30, 2023Three Months Ended September 30, 2022
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $987 $987 $— $1,001 $1,001 
Other— 381 381 — 325 325 
Total— 1,368 1,368 — 1,326 1,326 
Nutritionals —    
Pediatric Nutritionals506 495 1,001 357 470 827 
Adult Nutritionals354 718 1,072 329 639 968 
Total860 1,213 2,073 686 1,109 1,795 
Diagnostics —     
Core Laboratory317 997 1,314 281 938 1,219 
Molecular38 95 133 65 118 183 
Point of Care97 43 140 92 35 127 
Rapid Diagnostics561 301 862 1,273 839 2,112 
Total1,013 1,436 2,449 1,711 1,930 3,641 
Medical Devices —    
Rhythm Management271 292 563 263 270 533 
Electrophysiology246 298 544 225 244 469 
Heart Failure217 67 284 207 51 258 
Vascular251 421 672 213 393 606 
Structural Heart223 264 487 207 213 420 
Neuromodulation188 39 227 156 36 192 
Diabetes Care 544 928 1,472 423 744 1,167 
Total1,940 2,309 4,249 1,694 1,951 3,645 
Other4 — 4 3 — 3 
Total$3,817 $6,326 $10,143 $4,094 $6,316 $10,410 
Nine Months Ended September 30, 2023Nine Months Ended September 30, 2022
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,889 $2,889 $— $2,853 $2,853 
Other— 955 955 — 843 843 
Total— 3,844 3,844 — 3,696 3,696 
Nutritionals —    
Pediatric Nutritionals1,472 1,477 2,949 1,108 1,491 2,599 
Adult Nutritionals1,081 2,086 3,167 1,016 2,027 3,043 
Total2,553 3,563 6,116 2,124 3,518 5,642 
Diagnostics —
Core Laboratory917 2,872 3,789 836 2,788 3,624 
Molecular128 293 421 308 507 815 
Point of Care289 127 416 284 110 394 
Rapid Diagnostics1,975 853 2,828 5,436 2,923 8,359 
Total3,309 4,145 7,454 6,864 6,328 13,192 
Medical Devices —
Rhythm Management800 873 1,673 775 830 1,605 
Electrophysiology729 873 1,602 667 773 1,440 
Heart Failure661 199 860 610 167 777 
Vascular733 1,271 2,004 650 1,228 1,878 
Structural Heart652 794 1,446 604 667 1,271 
Neuromodulation528 122 650 456 112 568 
Diabetes Care1,528 2,681 4,209 1,165 2,320 3,485 
Total5,631 6,813 12,444 4,927 6,097 11,024 
Other10 — 10 8 — 8 
Total$11,503 $18,365 $29,868 $13,923 $19,639 $33,562 

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.

Remaining Performance Obligations

As of September 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.2 billion in the Diagnostics segment and approximately $456 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2022$500 
Unearned revenue from cash received during the period346 
Revenue recognized related to contract liability balance(292)
Balance at September 30, 2023$554 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Financial Information
 9 Months Ended
Sep. 30, 2023
Disclosure Text Block Supplement [Abstract]  
Supplemental Financial Information
Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2023 and 2022 were $1.431 billion and $1.429 billion, respectively, and for the nine months ended September 30, 2023 and 2022 were $4.113 billion and $5.876 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2023 includes $302 million of pension contributions and the payment of cash taxes of approximately $1.180 billion. The first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million.

The following summarizes the activity for the first nine months of 2023 related to the allowance for doubtful accounts as of September 30, 2023:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022$262 
Provisions/charges to income22 
Amounts charged off and other deductions(25)
Balance at September 30, 2023$259 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments as of September 30, 2023 and December 31, 2022 are as follows:

(in millions)September 30,
2023		December 31,
2022
Long-term Investments:
Equity securities$566 $558 
Other222 208 
Total$788 $766 

The increase in Abbott’s long-term investments as of September 30, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.

Abbott’s equity securities as of September 30, 2023 include $291 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of September 30, 2023 with a carrying value of $175 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $87 million that do not have a readily determinable fair value.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Changes In Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Changes In Accumulated Other Comprehensive Income (Loss)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202320222023202220232022
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
Other comprehensive income (loss) before reclassifications(497)(1,008)(9)15 96 278 
Amounts reclassified from accumulated other comprehensive income17 — — 41 (16)(65)
Net current period comprehensive income (loss)(480)(1,008)(9)56 80 213 
Balance at September 30$(7,126)$(7,268)$(1,506)$(2,498)$152 $321 
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20232022202320222023 2022
Balance at January 1$(6,733)$(5,839)$(1,493)$(2,670)$175 $135 
Other comprehensive income (loss) before reclassifications(410)(1,429)(6)45 134 289 
Amounts reclassified from accumulated other comprehensive income 17 — (7)127 (157)(103)
Net current period comprehensive income (loss)(393)(1,429)(13)172 (23)186 
Balance at September 30$(7,126)$(7,268)$(1,506)$(2,498)$152 $321 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Business Acquisitions
 9 Months Ended
Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Acquisitions
Note 6 — Business Acquisitions

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management even more personal and precise. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.
The preliminary allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets of $305 million; non-deductible in-process research and development of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $384 million; net deferred tax assets of approximately $31 million and other net assets of approximately $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill and Intangible Assets
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $23.3 billion at September 30, 2023 and $22.8 billion at December 31, 2022. Recent business acquisitions increased goodwill by approximately $590 million and foreign currency translation adjustments decreased goodwill by approximately $112 million in the first nine months of 2023. The amount of goodwill related to reportable segments at September 30, 2023 was $2.6 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.8 billion for the Medical Devices segment. There were no reductions of goodwill relating to impairments in the first nine months of 2023.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.2 billion as of September 30, 2023 and December 31, 2022, respectively. The gross amount of amortizable intangible assets increased by $305 million due to a recent business acquisition. Accumulated amortization was $19.0 billion and $17.6 billion as of September 30, 2023 and December 31, 2022, respectively. Foreign currency translation adjustments decreased intangible assets by $14 million in the first nine months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were approximately $832 million as of September 30, 2023 and $807 million as of December 31, 2022. Recent business acquisitions increased IPR&D by $80 million. This increase was partially offset by $55 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Plans
 9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Plans
Note 8 — Restructuring Plans

In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the nine months ended September 30, 2023, Abbott recorded employee related severance and other charges of approximately $102 million, of which approximately $31 million was recorded in Cost of products sold, approximately $16 million was recorded in Research and development, and approximately $55 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $29 million related to these restructuring plans.

The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2023:

(in millions)Total
Accrued balance at December 31, 2022$228 
Restructuring charges in 2023102 
Payments and other adjustments(181)
Accrued balance at September 30, 2023$149 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Incentive Stock Programs
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Incentive Stock Programs
Note 9 — Incentive Stock Programs

In the first nine months of 2023, Abbott granted 1,986,671 stock options, 463,856 restricted stock awards and 4,927,476 restricted stock units under its incentive stock program. At September 30, 2023, approximately 74 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2023 is as follows:

OutstandingExercisable
Number of shares 29,342,041 24,718,236 
Weighted average remaining life (years)
5.04.3
Weighted average exercise price $73.77 $66.27 
Aggregate intrinsic value (in millions)
$825 $825 

The total unrecognized share-based compensation cost at September 30, 2023 amounted to approximately $560 million which is expected to be recognized over the next three years.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Debt and Lines of Credit
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Debt and Lines of Credit
Note 10 — Debt and Lines of Credit

On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity. The repayment equated to approximately $1.2 billion. In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition. On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments, Derivatives and Fair Value Measures
Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.3 billion at September 30, 2023 and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2023 and December 31, 2022, Abbott held the gross notional amounts of $14.2 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $401 million and $446 million as of September 30, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at September 30, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2023 and December 31, 2022:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30,
2023		December 31, 2022Balance Sheet CaptionSeptember 30,
2023		December 31, 2022Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$— $— Deferred income taxes and other assets$158 $136 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables13 20 Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments254 304 Prepaid expenses and other receivables63 96 Other accrued liabilities
Others not designated as hedges113 108 Prepaid expenses and other receivables115 130 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a401 446 Long-term debt
$367 $412 $750 $828 
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2023 and 2022.

Gain (loss) Recognized in Other
Comprehensive Income (loss)		Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023202220232022Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$125 $350 $152 $442 $22 $79 $211 $149 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary12 24 45 108 n/an/an/an/an/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(18)(85)(15)(253)Interest expense

A gain of $60 million and a loss of $27 million were recognized in the three months ended September 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A loss of $4 million and a gain of $225 million were recognized in the first nine months ended September 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2023December 31, 2022
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$566 $566 $558 $558 
Other222 222 208 208 
Total Long-term Debt(15,528)(14,681)(16,773)(16,313)
Foreign Currency Forward Exchange Contracts:   
Receivable position367 367 412 412 
(Payable) position(178)(178)(226)(226)
Interest Rate Hedge Contracts:    
Receivable position— — — — 
(Payable) position(171)(171)(156)(156)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
September 30, 2023:
Equity securities$304 $304 $— $— 
Foreign currency forward exchange contracts367 — 367 — 
Total Assets$671 $304 $367 $— 
Fair value of hedged long-term debt$2,702 $— $2,702 $— 
Interest rate swap derivative financial instruments171 — 171 — 
Foreign currency forward exchange contracts178 — 178 — 
Contingent consideration related to business combinations109 — — 109 
Total Liabilities$3,160 $— $3,051 $109 
December 31, 2022:
Equity securities$307 $307 $— $— 
Foreign currency forward exchange contracts412 — 412 — 
Total Assets$719 $307 $412 $— 
Fair value of hedged long-term debt$2,691 $— $2,691 $— 
Interest rate swap derivative financial instruments156 156 
Foreign currency forward exchange contracts226 — 226 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,203 $— $3,073 $130 
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2022 reflects the impact of projected timeline changes for events that will trigger payment of contingent consideration, partially offset by additional contingent consideration due to a recent business acquisition.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Litigation and Environmental Matters
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Litigation and Environmental Matters
Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $25 million to $35 million. The recorded accrual balance at September 30, 2023 for these proceedings and exposures was approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Post-Employment Benefits
 9 Months Ended
Sep. 30, 2023
Postemployment Benefits [Abstract]  
Post-Employment Benefits
Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023202220232022
Service cost - benefits earned during the period$56 $92 $174 $282 $10 $13 $29 $38 
Interest cost on projected benefit obligations114 74 342 225 15 9 45 27 
Expected return on plan assets(244)(231)(729)(701)(6)(8)(18)(23)
Curtailment gain— — (14)— — — — — 
Net amortization of:
Actuarial loss, net2 58 8 174 (1)2 (2)8 
Prior service cost (credit)1 — 1 1 (3)(6)(10)(18)
Net cost (credit)$(71)$(7)$(218)$(19)$15 $10 $44 $32 

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2023 and 2022, $302 million and $362 million, respectively, were contributed to defined benefit plans. In the first nine months of 2023 and 2022, $28 million was contributed, in each year, to the post-employment medical and dental plans.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Taxes on Earnings
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Taxes on Earnings
Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2023 and 2022, taxes on earnings include approximately $11 million and $36 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2023 and 2022, taxes on earnings also include approximately $59 million and $20 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $55 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott expects to file a petition with the U.S. Tax Court contesting the 2019 SNOD in December of 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15% minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have indicated their intent to adopt the proposal and are drafting legislation to implement the Pillar 2 model rules with a subset of the rules becoming effective January 1, 2024, and the remaining rules becoming effective January 1, 2025, or in later periods. Abbott is also continuing to analyze the Pillar 2 model rules. Implementation of the OECD proposal may have a material impact on Abbott’s Condensed Consolidated Financial Statements in the future.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Information
Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023 2022 2023 2022
Established Pharmaceutical Products$1,368 $1,326 $3,844 $3,696 $345 $331 $952 $831 
Nutritional Products2,073 1,795 6,116 5,642 284 69 972 550 
Diagnostic Products2,449 3,641 7,454 13,192 632 1,346 1,720 5,615 
Medical Devices4,249 3,645 12,444 11,024 1,342 1,045 3,805 3,288 
Total Reportable Segments10,139 10,407 29,858 33,554 2,603 2,791 7,449 10,284 
Other 4 3 10 8 
Net sales$10,143 $10,410 $29,868 $33,562 
Corporate functions and benefit plan costs(50)(115)(198)(352)
Net interest expense (69)(86)(182)(309)
Share-based compensation (a) (117)(123)(530)(570)
Amortization of intangible assets(496)(498)(1,485)(1,517)
Other, net (b)(200)(211)(185)(550)
Earnings before taxes$1,671 $1,758 $4,869 $6,986 
______________________________________
Notes:Three and nine months ended September 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI and charges related to restructuring actions and intangible asset and investment impairments. Other, net for the nine months ended September 30, 2023 also includes income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment, $111 million of charges related to the impairment of IPR&D intangible assets as well as integration costs related to the acquisition of Alere Inc. and restructuring charges.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
New Accounting Standards (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
Recently Adopted Accounting Standards Recently Adopted Accounting StandardsIn September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Sales Category
The following tables provide detail by sales category:

Three Months Ended September 30, 2023Three Months Ended September 30, 2022
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $987 $987 $— $1,001 $1,001 
Other— 381 381 — 325 325 
Total— 1,368 1,368 — 1,326 1,326 
Nutritionals —    
Pediatric Nutritionals506 495 1,001 357 470 827 
Adult Nutritionals354 718 1,072 329 639 968 
Total860 1,213 2,073 686 1,109 1,795 
Diagnostics —     
Core Laboratory317 997 1,314 281 938 1,219 
Molecular38 95 133 65 118 183 
Point of Care97 43 140 92 35 127 
Rapid Diagnostics561 301 862 1,273 839 2,112 
Total1,013 1,436 2,449 1,711 1,930 3,641 
Medical Devices —    
Rhythm Management271 292 563 263 270 533 
Electrophysiology246 298 544 225 244 469 
Heart Failure217 67 284 207 51 258 
Vascular251 421 672 213 393 606 
Structural Heart223 264 487 207 213 420 
Neuromodulation188 39 227 156 36 192 
Diabetes Care 544 928 1,472 423 744 1,167 
Total1,940 2,309 4,249 1,694 1,951 3,645 
Other4 — 4 3 — 3 
Total$3,817 $6,326 $10,143 $4,094 $6,316 $10,410 
Nine Months Ended September 30, 2023Nine Months Ended September 30, 2022
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,889 $2,889 $— $2,853 $2,853 
Other— 955 955 — 843 843 
Total— 3,844 3,844 — 3,696 3,696 
Nutritionals —    
Pediatric Nutritionals1,472 1,477 2,949 1,108 1,491 2,599 
Adult Nutritionals1,081 2,086 3,167 1,016 2,027 3,043 
Total2,553 3,563 6,116 2,124 3,518 5,642 
Diagnostics —
Core Laboratory917 2,872 3,789 836 2,788 3,624 
Molecular128 293 421 308 507 815 
Point of Care289 127 416 284 110 394 
Rapid Diagnostics1,975 853 2,828 5,436 2,923 8,359 
Total3,309 4,145 7,454 6,864 6,328 13,192 
Medical Devices —
Rhythm Management800 873 1,673 775 830 1,605 
Electrophysiology729 873 1,602 667 773 1,440 
Heart Failure661 199 860 610 167 777 
Vascular733 1,271 2,004 650 1,228 1,878 
Structural Heart652 794 1,446 604 667 1,271 
Neuromodulation528 122 650 456 112 568 
Diabetes Care1,528 2,681 4,209 1,165 2,320 3,485 
Total5,631 6,813 12,444 4,927 6,097 11,024 
Other10 — 10 8 — 8 
Total$11,503 $18,365 $29,868 $13,923 $19,639 $33,562 

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.
Schedule of Changes in Contract Liabilities
Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2022$500 
Unearned revenue from cash received during the period346 
Revenue recognized related to contract liability balance(292)
Balance at September 30, 2023$554 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Financial Information (Tables)
 9 Months Ended
Sep. 30, 2023
Disclosure Text Block Supplement [Abstract]  
Summary of Allowance for Doubtful Accounts Activity
The following summarizes the activity for the first nine months of 2023 related to the allowance for doubtful accounts as of September 30, 2023:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022$262 
Provisions/charges to income22 
Amounts charged off and other deductions(25)
Balance at September 30, 2023$259 
Schedule of Long-term Investments
The components of long-term investments as of September 30, 2023 and December 31, 2022 are as follows:

(in millions)September 30,
2023		December 31,
2022
Long-term Investments:
Equity securities$566 $558 
Other222 208 
Total$788 $766 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Changes In Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202320222023202220232022
Balance at June 30$(6,646)$(6,260)$(1,497)$(2,554)$72 $108 
Other comprehensive income (loss) before reclassifications(497)(1,008)(9)15 96 278 
Amounts reclassified from accumulated other comprehensive income17 — — 41 (16)(65)
Net current period comprehensive income (loss)(480)(1,008)(9)56 80 213 
Balance at September 30$(7,126)$(7,268)$(1,506)$(2,498)$152 $321 
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20232022202320222023 2022
Balance at January 1$(6,733)$(5,839)$(1,493)$(2,670)$175 $135 
Other comprehensive income (loss) before reclassifications(410)(1,429)(6)45 134 289 
Amounts reclassified from accumulated other comprehensive income 17 — (7)127 (157)(103)
Net current period comprehensive income (loss)(393)(1,429)(13)172 (23)186 
Balance at September 30$(7,126)$(7,268)$(1,506)$(2,498)$152 $321 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Plans (Tables)
 9 Months Ended
Sep. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Activity and Related Accruals
The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2023:

(in millions)Total
Accrued balance at December 31, 2022$228 
Restructuring charges in 2023102 
Payments and other adjustments(181)
Accrued balance at September 30, 2023$149 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Incentive Stock Programs (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Options Outstanding and Exercisable Information regarding the number of options outstanding and exercisable at September 30, 2023 is as follows:
OutstandingExercisable
Number of shares 29,342,041 24,718,236 
Weighted average remaining life (years)
5.04.3
Weighted average exercise price $73.77 $66.27 
Aggregate intrinsic value (in millions)
$825 $825 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Amounts and Location of Derivative Financial Instruments
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2023 and December 31, 2022:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30,
2023		December 31, 2022Balance Sheet CaptionSeptember 30,
2023		December 31, 2022Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current$— $— Deferred income taxes and other assets$158 $136 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables13 20 Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments254 304 Prepaid expenses and other receivables63 96 Other accrued liabilities
Others not designated as hedges113 108 Prepaid expenses and other receivables115 130 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a401 446 Long-term debt
$367 $412 $750 $828 
Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2023 and 2022.

Gain (loss) Recognized in Other
Comprehensive Income (loss)		Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023202220232022Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$125 $350 $152 $442 $22 $79 $211 $149 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary12 24 45 108 n/an/an/an/an/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(18)(85)(15)(253)Interest expense
Schedule of Carrying Values and Fair Values of Financial Instruments
The carrying values and fair values of certain financial instruments as of September 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2023December 31, 2022
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$566 $566 $558 $558 
Other222 222 208 208 
Total Long-term Debt(15,528)(14,681)(16,773)(16,313)
Foreign Currency Forward Exchange Contracts:   
Receivable position367 367 412 412 
(Payable) position(178)(178)(226)(226)
Interest Rate Hedge Contracts:    
Receivable position— — — — 
(Payable) position(171)(171)(156)(156)
Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
September 30, 2023:
Equity securities$304 $304 $— $— 
Foreign currency forward exchange contracts367 — 367 — 
Total Assets$671 $304 $367 $— 
Fair value of hedged long-term debt$2,702 $— $2,702 $— 
Interest rate swap derivative financial instruments171 — 171 — 
Foreign currency forward exchange contracts178 — 178 — 
Contingent consideration related to business combinations109 — — 109 
Total Liabilities$3,160 $— $3,051 $109 
December 31, 2022:
Equity securities$307 $307 $— $— 
Foreign currency forward exchange contracts412 — 412 — 
Total Assets$719 $307 $412 $— 
Fair value of hedged long-term debt$2,691 $— $2,691 $— 
Interest rate swap derivative financial instruments156 156 
Foreign currency forward exchange contracts226 — 226 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,203 $— $3,073 $130 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Post-Employment Benefits (Tables)
 9 Months Ended
Sep. 30, 2023
Postemployment Benefits [Abstract]  
Schedule of Net Periodic Benefit Costs Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Defined Benefit PlansMedical and Dental Plans
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023202220232022
Service cost - benefits earned during the period$56 $92 $174 $282 $10 $13 $29 $38 
Interest cost on projected benefit obligations114 74 342 225 15 9 45 27 
Expected return on plan assets(244)(231)(729)(701)(6)(8)(18)(23)
Curtailment gain— — (14)— — — — — 
Net amortization of:
Actuarial loss, net2 58 8 174 (1)2 (2)8 
Prior service cost (credit)1 — 1 1 (3)(6)(10)(18)
Net cost (credit)$(71)$(7)$(218)$(19)$15 $10 $44 $32 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Information
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20232022202320222023 2022 2023 2022
Established Pharmaceutical Products$1,368 $1,326 $3,844 $3,696 $345 $331 $952 $831 
Nutritional Products2,073 1,795 6,116 5,642 284 69 972 550 
Diagnostic Products2,449 3,641 7,454 13,192 632 1,346 1,720 5,615 
Medical Devices4,249 3,645 12,444 11,024 1,342 1,045 3,805 3,288 
Total Reportable Segments10,139 10,407 29,858 33,554 2,603 2,791 7,449 10,284 
Other 4 3 10 8 
Net sales$10,143 $10,410 $29,868 $33,562 
Corporate functions and benefit plan costs(50)(115)(198)(352)
Net interest expense (69)(86)(182)(309)
Share-based compensation (a) (117)(123)(530)(570)
Amortization of intangible assets(496)(498)(1,485)(1,517)
Other, net (b)(200)(211)(185)(550)
Earnings before taxes$1,671 $1,758 $4,869 $6,986 
______________________________________
Notes:Three and nine months ended September 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI and charges related to restructuring actions and intangible asset and investment impairments. Other, net for the nine months ended September 30, 2023 also includes income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment, $111 million of charges related to the impairment of IPR&D intangible assets as well as integration costs related to the acquisition of Alere Inc. and restructuring charges.
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
segment
Sep. 30, 2022
segment
Sep. 30, 2023
USD ($)
segment
Sep. 30, 2022
segment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Number of reportable segments | segment 4 4 4 4
Diagnostics        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 4,200   $ 4,200  
Medical Devices        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 456   $ 456  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     59.00%  
Expected timing of satisfaction period (in months) 24 months   24 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     17.00%  
Expected timing of satisfaction period (in months) 12 months   12 months  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Summary of Revenue by Sales Category (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Net sales $ 10,143 $ 10,410 $ 29,868 $ 33,562
Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 10,139 10,407 29,858 33,554
Other        
Segment Reporting Information [Line Items]        
Net sales 4 3 10 8
United States        
Segment Reporting Information [Line Items]        
Net sales 3,817 4,094 11,503 13,923
United States | Other        
Segment Reporting Information [Line Items]        
Net sales 4 3 10 8
International        
Segment Reporting Information [Line Items]        
Net sales 6,326 6,316 18,365 19,639
International | Other        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,368 1,326 3,844 3,696
Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,368 1,326 3,844 3,696
Nutritionals | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,073 1,795 6,116 5,642
Nutritionals | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 860 686 2,553 2,124
Nutritionals | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,213 1,109 3,563 3,518
Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,449 3,641 7,454 13,192
Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,013 1,711 3,309 6,864
Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,436 1,930 4,145 6,328
Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 4,249 3,645 12,444 11,024
Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,940 1,694 5,631 4,927
Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,309 1,951 6,813 6,097
Key Emerging Markets | Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 987 1,001 2,889 2,853
Key Emerging Markets | Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Key Emerging Markets | Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 987 1,001 2,889 2,853
Other | Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 381 325 955 843
Other | Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Other | Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 381 325 955 843
Pediatric Nutritionals | Nutritionals | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,001 827 2,949 2,599
Pediatric Nutritionals | Nutritionals | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 506 357 1,472 1,108
Pediatric Nutritionals | Nutritionals | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 495 470 1,477 1,491
Adult Nutritionals | Nutritionals | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,072 968 3,167 3,043
Adult Nutritionals | Nutritionals | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 354 329 1,081 1,016
Adult Nutritionals | Nutritionals | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 718 639 2,086 2,027
Core Laboratory | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,314 1,219 3,789 3,624
Core Laboratory | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 317 281 917 836
Core Laboratory | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 997 938 2,872 2,788
Molecular | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 133 183 421 815
Molecular | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 38 65 128 308
Molecular | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 95 118 293 507
Point of Care | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 140 127 416 394
Point of Care | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 97 92 289 284
Point of Care | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 43 35 127 110
Rapid Diagnostics | Diagnostics | Revision of Prior Period, Reclassification, Adjustment        
Segment Reporting Information [Line Items]        
Net sales   (30)   (87)
Rapid Diagnostics | Diagnostics | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 862 2,112 2,828 8,359
Rapid Diagnostics | Diagnostics | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 561 1,273 1,975 5,436
Rapid Diagnostics | Diagnostics | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 301 839 853 2,923
Rhythm Management | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 563 533 1,673 1,605
Rhythm Management | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 271 263 800 775
Rhythm Management | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 292 270 873 830
Electrophysiology | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 544 469 1,602 1,440
Electrophysiology | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 246 225 729 667
Electrophysiology | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 298 244 873 773
Heart Failure | Medical Devices | Revision of Prior Period, Reclassification, Adjustment        
Segment Reporting Information [Line Items]        
Net sales   30   87
Heart Failure | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 284 258 860 777
Heart Failure | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 217 207 661 610
Heart Failure | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 67 51 199 167
Vascular | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 672 606 2,004 1,878
Vascular | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 251 213 733 650
Vascular | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 421 393 1,271 1,228
Structural Heart | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 487 420 1,446 1,271
Structural Heart | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 223 207 652 604
Structural Heart | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 264 213 794 667
Neuromodulation | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 227 192 650 568
Neuromodulation | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 188 156 528 456
Neuromodulation | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 39 36 122 112
Diabetes Care | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,472 1,167 4,209 3,485
Diabetes Care | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 544 423 1,528 1,165
Diabetes Care | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales $ 928 $ 744 $ 2,681 $ 2,320
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Schedule of Changes in Contract Liabilities (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Contract Liabilities:  
Beginning balance $ 500
Unearned revenue from cash received during the period 346
Revenue recognized related to contract liability balance (292)
Ending balance $ 554
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Financial Information - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Cash Flow Statements, Captions [Line Items]        
Net earnings allocated to common shares $ 1,431 $ 1,429 $ 4,113 $ 5,876
Payment of cash taxes     1,180 987
Equity method investments carrying value 175   175  
Equity investments without readily determinable fair value 87   87  
St. Jude Medical | Equity securities        
Condensed Cash Flow Statements, Captions [Line Items]        
Investments in mutual funds held in a rabbi trust $ 291   291  
Defined Benefit Plans        
Condensed Cash Flow Statements, Captions [Line Items]        
Pension contributions     $ 302 $ 362
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Financial Information - Allowance for Doubtful Accounts (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Allowance for Doubtful Accounts:  
Beginning balance $ 262
Provisions/charges to income 22
Amounts charged off and other deductions (25)
Ending balance $ 259
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Financial Information - Investments (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Summary of Investment Holdings [Line Items]    
Total $ 788 $ 766
Equity securities    
Summary of Investment Holdings [Line Items]    
Total 566 558
Other    
Summary of Investment Holdings [Line Items]    
Total $ 222 $ 208
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Changes In Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period     $ 36,686  
Other comprehensive income (loss) $ (409) $ (739) (429) $ (1,071)
End of the period 37,481   37,481  
Cumulative Foreign Currency Translation (Loss) Adjustments        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period (6,646) (6,260) (6,733) (5,839)
Other comprehensive income (loss) before reclassifications (497) (1,008) (410) (1,429)
Amounts reclassified from accumulated other comprehensive income 17 0 17 0
Other comprehensive income (loss) (480) (1,008) (393) (1,429)
End of the period (7,126) (7,268) (7,126) (7,268)
Net Actuarial (Losses) and Prior Service (Costs) and Credits        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period (1,497) (2,554) (1,493) (2,670)
Other comprehensive income (loss) before reclassifications (9) 15 (6) 45
Amounts reclassified from accumulated other comprehensive income 0 41 (7) 127
Other comprehensive income (loss) (9) 56 (13) 172
End of the period (1,506) (2,498) (1,506) (2,498)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period 72 108 175 135
Other comprehensive income (loss) before reclassifications 96 278 134 289
Amounts reclassified from accumulated other comprehensive income (16) (65) (157) (103)
Other comprehensive income (loss) 80 213 (23) 186
End of the period $ 152 $ 321 $ 152 $ 321
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Business Acquisitions (Details)
$ / shares in Units, $ in Millions
Apr. 27, 2023
USD ($)
intangibleAsset
$ / shares
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]      
Goodwill   $ 23,277 $ 22,799
CSI      
Business Acquisition [Line Items]      
Acquisition share price (in dollars per share) | $ / shares $ 20    
Acquisition purchase price $ 851    
Number of developed technology intangible assets | intangibleAsset 2    
Developed technology intangible assets $ 305    
In-process research and development 15    
Goodwill 384    
Net deferred tax assets 31    
Other net assets $ 116    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill and Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Goodwill and Intangible Assets [Line Items]        
Goodwill   $ 23,277   $ 22,799
Increase in goodwill due to acquisition   590    
Decrease in goodwill due to foreign currency translation adjustments   112    
Amount of reductions of goodwill relating to impairments   0    
Gross amount of amortizable intangible assets   27,500   27,200
Increase in amortizable intangible assets due to acquisition   305    
Accumulated amortization of intangible assets   19,000   17,600
Decrease in intangible assets due to foreign currency translation adjustments   14    
Estimated annual amortization expense, intangible assets, 2023   2,000    
Estimated annual amortization expense, intangible assets, 2024   1,900    
Estimated annual amortization expense, intangible assets, 2025   1,700    
Estimated annual amortization expense, intangible assets, 2026   1,600    
Estimated annual amortization expense, intangible assets, 2027   1,300    
Indefinite-lived intangible assets related to in-process R&D acquired in a business combination   832   $ 807
Increase in in-process R&D due to acquisition   80    
Established Pharmaceutical Products        
Goodwill and Intangible Assets [Line Items]        
Goodwill   2,600    
Nutritional Products        
Goodwill and Intangible Assets [Line Items]        
Goodwill   285    
Diagnostic Products        
Goodwill and Intangible Assets [Line Items]        
Goodwill   3,500    
Medical Devices        
Goodwill and Intangible Assets [Line Items]        
Goodwill   16,800    
Impairment of indefinite-lived intangible assets $ 111 $ 55 $ 111  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Plans - Narrative (Details) - 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Restructuring Cost and Reserve [Line Items]  
Restructuring charges $ 102
Fixed asset impairment charges 29
Cost of products sold  
Restructuring Cost and Reserve [Line Items]  
Restructuring charges 31
Research and Development  
Restructuring Cost and Reserve [Line Items]  
Restructuring charges 16
Selling, General and Administrative Expenses  
Restructuring Cost and Reserve [Line Items]  
Restructuring charges $ 55
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Plans - Restructuring Activity and Related Accruals (Details) - 2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Restructuring Reserve [Roll Forward]  
Accrued balance at beginning of the period $ 228
Restructuring charges in 2023 102
Payments and other adjustments (181)
Accrued balance at end of the period $ 149
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Incentive Stock Programs - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Incentive stock program, shares reserved for future grants (in shares) 74,000,000
Total unrecognized compensation cost | $ $ 560
Total unrecognized compensation cost, recognition period 3 years
Stock Options  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options granted during the period (in shares) 1,986,671
Restricted Stock Awards  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock awards granted during the period (in shares) 463,856
Restricted Stock Units (RSUs)  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock units granted during period (in shares) 4,927,476
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Incentive Stock Programs - Options (Details) - Stock Options
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options outstanding, number of shares | shares 29,342,041
Exercisable options, number of shares | shares 24,718,236
Stock options outstanding, weighted-average remaining life 5 years
Exercisable options, weighted-average remaining life 4 years 3 months 18 days
Stock options outstanding, weighted-average exercise price (in dollars per share) | $ / shares $ 73.77
Exercisable options, weighted-average exercise price (in dollars per share) | $ / shares $ 66.27
Aggregate intrinsic value of options outstanding | $ $ 825
Aggregate intrinsic value of options exercisable | $ $ 825
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Debt and Lines of Credit (Details)
€ in Millions, $ in Millions
 1 Months Ended
Sep. 27, 2023
EUR (€)
Sep. 27, 2023
USD ($)
Mar. 15, 2022
USD ($)
Sep. 30, 2023
USD ($)
Bigfoot        
Debt Instrument [Line Items]        
Repayments of debt       $ 197
0.875% Long-term Notes Due 2023        
Debt Instrument [Line Items]        
Repayments of debt € 1,140 $ 1,200    
Interest rate percentage 0.875% 0.875%    
2.55% Long-term Notes Due 2022        
Debt Instrument [Line Items]        
Repayments of debt     $ 750  
Interest rate percentage     2.55%  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Derivative [Line Items]          
Yen-denominated term loan $ 750   $ 750   $ 828
Net Investment Hedging | Designated as Hedging Instrument | Five Year Term Loan due 2024          
Derivative [Line Items]          
Debt instrument, term     5 years   5 years
Yen-denominated term loan 401   $ 401   $ 446
Foreign Currency Forward Exchange Contracts          
Derivative [Line Items]          
Gain (loss) from foreign currency forward exchange contracts not designated as hedges 60 $ (27) (4) $ 225  
Foreign Currency Forward Exchange Contracts | Not Designated as Hedging Instrument          
Derivative [Line Items]          
Derivative, notional amount 14,200   14,200   12,000
Foreign Currency Forward Exchange Contracts | Cash Flow Hedging | Designated as Hedging Instrument          
Derivative [Line Items]          
Derivative, notional amount 7,300   $ 7,300   7,700
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold     12 months    
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold     18 months    
Interest Rate Hedge Contracts | Fair Value Hedging | Designated as Hedging Instrument          
Derivative [Line Items]          
Derivative, notional amount $ 2,900   $ 2,900   $ 2,900
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Derivatives, Fair Value [Line Items]    
Fair Value - Assets $ 367 $ 412
Fair Value - Liabilities 750 828
Designated as Hedging Instrument | Interest Rate Swaps | Deferred income taxes and other assets | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 0
Designated as Hedging Instrument | Interest Rate Swaps | Prepaid expenses and other receivables, current | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 0
Designated as Hedging Instrument | Interest Rate Swaps | Post-employment obligations, deferred income taxes and other long-term liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 158 136
Designated as Hedging Instrument | Interest Rate Swaps | Other accrued liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 13 20
Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 254 304
Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 63 96
Designated as Hedging Instrument | Debt | Long-term debt | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 401 446
Not Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 113 108
Not Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities $ 115 $ 130
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Foreign Currency Forward Exchange Contracts | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges $ 125 $ 350 $ 152 $ 442
Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges 22 79 211 149
Debt        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary 12 24 45 108
Interest Rate Swaps | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges $ (18) $ (85) $ (15) $ (253)
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Derivative [Line Items]    
Long-term Investment Securities: $ 788 $ 766
Receivable position 367 412
(Payable) position (750) (828)
Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 566 558
Carrying Value    
Derivative [Line Items]    
Total Long-term Debt (15,528) (16,773)
Carrying Value | Foreign Currency Forward Exchange Contracts    
Derivative [Line Items]    
Receivable position 367 412
(Payable) position (178) (226)
Carrying Value | Interest Rate Hedge Contracts    
Derivative [Line Items]    
Receivable position 0 0
(Payable) position (171) (156)
Carrying Value | Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 566 558
Carrying Value | Other    
Derivative [Line Items]    
Long-term Investment Securities: 222 208
Fair Value    
Derivative [Line Items]    
Total Long-term Debt (14,681) (16,313)
Fair Value | Foreign Currency Forward Exchange Contracts    
Derivative [Line Items]    
Receivable position 367 412
(Payable) position (178) (226)
Fair Value | Interest Rate Hedge Contracts    
Derivative [Line Items]    
Receivable position 0 0
(Payable) position (171) (156)
Fair Value | Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 566 558
Fair Value | Other    
Derivative [Line Items]    
Long-term Investment Securities: $ 222 $ 208
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Quoted Prices in Active Markets    
Assets, at Fair Value    
Equity securities $ 304 $ 307
Foreign currency forward exchange contracts 0 0
Total Assets 304 307
Liabilities, at Fair Value    
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 0 0
Total Liabilities 0 0
Significant Other Observable Inputs    
Assets, at Fair Value    
Equity securities 0 0
Foreign currency forward exchange contracts 367 412
Total Assets 367 412
Liabilities, at Fair Value    
Fair value of hedged long-term debt 2,702 2,691
Interest rate swap derivative financial instruments 171 156
Foreign currency forward exchange contracts 178 226
Contingent consideration related to business combinations 0 0
Total Liabilities 3,051 3,073
Significant Unobservable Inputs    
Assets, at Fair Value    
Equity securities 0 0
Foreign currency forward exchange contracts 0 0
Total Assets 0 0
Liabilities, at Fair Value    
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 109 130
Total Liabilities 109 130
Outstanding Balances    
Assets, at Fair Value    
Equity securities 304 307
Foreign currency forward exchange contracts 367 412
Total Assets 671 719
Liabilities, at Fair Value    
Fair value of hedged long-term debt 2,702 2,691
Interest rate swap derivative financial instruments 171 156
Foreign currency forward exchange contracts 178 226
Contingent consideration related to business combinations 109 130
Total Liabilities $ 3,160 $ 3,203
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Litigation and Environmental Matters (Details)
$ in Millions
Sep. 30, 2023
USD ($)
Loss Contingencies [Line Items]  
Maximum expected cleanup exposure for individual site $ 4
Maximum expected cleanup exposure in aggregate 10
Legal proceedings and environmental exposures  
Loss Contingencies [Line Items]  
Recorded accrual balance for legal proceedings and exposures 30
Legal proceedings and environmental exposures | Minimum  
Loss Contingencies [Line Items]  
Estimation of possible loss 25
Legal proceedings and environmental exposures | Maximum  
Loss Contingencies [Line Items]  
Estimation of possible loss $ 35
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Defined Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost - benefits earned during the period $ 56 $ 92 $ 174 $ 282
Interest cost on projected benefit obligations 114 74 342 225
Expected return on plan assets (244) (231) (729) (701)
Curtailment gain 0 0 (14) 0
Net amortization of:        
Actuarial loss, net 2 58 8 174
Prior service cost (credit) 1 0 1 1
Net cost (credit) (71) (7) (218) (19)
Medical and Dental Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost - benefits earned during the period 10 13 29 38
Interest cost on projected benefit obligations 15 9 45 27
Expected return on plan assets (6) (8) (18) (23)
Curtailment gain 0 0 0 0
Net amortization of:        
Actuarial loss, net (1) 2 (2) 8
Prior service cost (credit) (3) (6) (10) (18)
Net cost (credit) $ 15 $ 10 $ 44 $ 32
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Post-Employment Benefits - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Defined Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 302 $ 362
Medical and Dental Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 28 $ 28
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Taxes on Earnings (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]    
Excess tax benefits associated with share-based compensation $ 11 $ 36
Tax expense from prior year tax positions 59 $ 20
Decrease reasonably possible in gross unrecognized tax benefits 55  
Income tax claim related to statutory notice of deficiency $ 417  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 10,143 $ 10,410 $ 29,868 $ 33,562
Operating Earnings 1,647 1,770 4,698 7,058
Amortization of intangible assets (496) (498) (1,485) (1,517)
Earnings before taxes $ 1,671 $ 1,758 $ 4,869 $ 6,986
Annual share-based awards recognized in first quarter (as a percent) 45.00% 45.00% 45.00% 45.00%
Nutritional Products        
Segment Reporting Information [Line Items]        
Inventory recall expense   $ 10   $ 172
Medical Devices        
Segment Reporting Information [Line Items]        
Impairment of IPR&D intangible assets   111 $ 55 111
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 10,139 10,407 29,858 33,554
Operating Earnings 2,603 2,791 7,449 10,284
Operating Segments | Established Pharmaceutical Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 1,368 1,326 3,844 3,696
Operating Earnings 345 331 952 831
Operating Segments | Nutritional Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,073 1,795 6,116 5,642
Operating Earnings 284 69 972 550
Operating Segments | Diagnostic Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 2,449 3,641 7,454 13,192
Operating Earnings 632 1,346 1,720 5,615
Operating Segments | Medical Devices        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 4,249 3,645 12,444 11,024
Operating Earnings 1,342 1,045 3,805 3,288
Other        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 4 3 10 8
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Corporate functions and benefit plan costs (50) (115) (198) (352)
Net interest expense (69) (86) (182) (309)
Share-based compensation (117) (123) (530) (570)
Amortization of intangible assets (496) (498) (1,485) (1,517)
Other, net $ (200) $ (211) $ (185) $ (550)
XML 68 abt-20230930_htm.xml IDEA: XBRL DOCUMENT 0000001800 2023-01-01 2023-09-30 0000001800 exch:XCHI 2023-01-01 2023-09-30 0000001800 exch:XNYS 2023-01-01 2023-09-30 0000001800 2023-09-30 0000001800 2023-07-01 2023-09-30 0000001800 2022-07-01 2022-09-30 0000001800 2022-01-01 2022-09-30 0000001800 2022-12-31 0000001800 us-gaap:CommonStockMember 2023-06-30 0000001800 us-gaap:CommonStockMember 2022-06-30 0000001800 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000001800 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000001800 us-gaap:CommonStockMember 2023-09-30 0000001800 us-gaap:CommonStockMember 2022-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2023-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2023-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-09-30 0000001800 us-gaap:RetainedEarningsMember 2023-06-30 0000001800 us-gaap:RetainedEarningsMember 2022-06-30 0000001800 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000001800 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000001800 us-gaap:RetainedEarningsMember 2023-09-30 0000001800 us-gaap:RetainedEarningsMember 2022-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2023-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2023-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-09-30 0000001800 us-gaap:CommonStockMember 2022-12-31 0000001800 us-gaap:CommonStockMember 2021-12-31 0000001800 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000001800 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2021-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-09-30 0000001800 us-gaap:RetainedEarningsMember 2022-12-31 0000001800 us-gaap:RetainedEarningsMember 2021-12-31 0000001800 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000001800 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2021-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0000001800 2021-12-31 0000001800 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2023-07-01 2023-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2022-07-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000001800 country:US 2023-07-01 2023-09-30 0000001800 us-gaap:NonUsMember 2023-07-01 2023-09-30 0000001800 country:US 2022-07-01 2022-09-30 0000001800 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2022-01-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2023-01-01 2023-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000001800 country:US 2023-01-01 2023-09-30 0000001800 us-gaap:NonUsMember 2023-01-01 2023-09-30 0000001800 country:US 2022-01-01 2022-09-30 0000001800 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 abt:DiagnosticProductsMember 2023-09-30 0000001800 abt:MedicalDevicesMember 2023-09-30 0000001800 2023-10-01 2023-01-01 2023-09-30 0000001800 2023-10-01 2023-09-30 0000001800 2025-10-01 2023-01-01 2023-09-30 0000001800 2025-10-01 2023-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000001800 us-gaap:EquitySecuritiesMember 2023-09-30 0000001800 us-gaap:EquitySecuritiesMember 2022-12-31 0000001800 us-gaap:OtherInvestmentsMember 2023-09-30 0000001800 us-gaap:OtherInvestmentsMember 2022-12-31 0000001800 abt:StJudeMedicalMember us-gaap:EquitySecuritiesMember 2023-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2023-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2023-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000001800 abt:CardiovascularSystemsIncMember 2023-04-27 0000001800 abt:CardiovascularSystemsIncMember 2023-04-27 2023-04-27 0000001800 abt:EstablishedPharmaceuticalProductsMember 2023-09-30 0000001800 abt:NutritionalProductsMember 2023-09-30 0000001800 abt:MedicalDevicesMember 2023-01-01 2023-09-30 0000001800 abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-09-30 0000001800 abt:CostOfGoodsAndServicesSoldMember abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-09-30 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-09-30 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-01-01 2023-09-30 0000001800 abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2022-12-31 0000001800 abt:A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember 2023-09-30 0000001800 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000001800 abt:RestrictedStockAwardsMember 2023-01-01 2023-09-30 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000001800 us-gaap:EmployeeStockOptionMember 2023-09-30 0000001800 abt:A0875LongTermNotesDue2023Member 2023-09-27 2023-09-27 0000001800 abt:A0875LongTermNotesDue2023Member 2023-09-27 0000001800 abt:BigfootBiomedicalMember 2023-09-01 2023-09-30 0000001800 abt:A255LongTermNotesDue2022Member 2022-03-15 2022-03-15 0000001800 abt:A255LongTermNotesDue2022Member 2022-03-15 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-09-30 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:PrepaidExpensesAndOtherReceivablesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-09-30 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-09-30 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-12-31 0000001800 abt:LongTermDebtExcludingCurrentMaturitiesMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000001800 abt:LongTermDebtExcludingCurrentMaturitiesMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2023-07-01 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2022-07-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2023-01-01 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2022-01-01 2022-09-30 0000001800 us-gaap:DebtMember 2023-07-01 2023-09-30 0000001800 us-gaap:DebtMember 2022-07-01 2022-09-30 0000001800 us-gaap:DebtMember 2023-01-01 2023-09-30 0000001800 us-gaap:DebtMember 2022-01-01 2022-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2023-07-01 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2022-07-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2023-01-01 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2023-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2023-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2022-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2022-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2023-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2023-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2022-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2022-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000001800 us-gaap:FairValueInputsLevel1Member 2023-09-30 0000001800 us-gaap:FairValueInputsLevel2Member 2023-09-30 0000001800 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000001800 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000001800 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000001800 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000001800 srt:MinimumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2023-09-30 0000001800 srt:MaximumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2023-09-30 0000001800 abt:LegalProceedingsAndEnvironmentalExposuresMember 2023-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2023-07-01 2023-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2022-07-01 2022-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-09-30 0000001800 abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 abt:MedicalDevicesMember 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares abt:segment pure abt:intangibleAsset iso4217:EUR 0000001800 --12-31 2023 Q3 false P12M 10-Q true 2023-09-30 false 1-2189 ABBOTT LABORATORIES IL 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX Yes Yes Large Accelerated Filer false false false 1736058536 10143000000 10410000000 29868000000 33562000000 4605000000 4629000000 13419000000 14549000000 496000000 498000000 1485000000 1517000000 672000000 782000000 2041000000 2163000000 2723000000 2731000000 8225000000 8275000000 8496000000 8640000000 25170000000 26504000000 1647000000 1770000000 4698000000 7058000000 166000000 141000000 478000000 404000000 97000000 55000000 296000000 95000000 10000000 -19000000 -17000000 -16000000 83000000 93000000 370000000 253000000 1671000000 1758000000 4869000000 6986000000 235000000 323000000 740000000 1086000000 1436000000 1435000000 4129000000 5900000000 0.82 0.82 2.36 3.35 0.82 0.81 2.35 3.32 1738700000 1752968000 1740255000 1756209000 9589000 10685000 9819000 11638000 1748289000 1763653000 1750074000 1767847000 7334000 5445000 5474000 2655000 1436000000 1435000000 4129000000 5900000000 -480000000 -1008000000 -393000000 -1429000000 -1000000 -4000000 11000000 36000000 9000000 -56000000 13000000 -172000000 30000000 -24000000 50000000 96000000 80000000 213000000 -23000000 186000000 -409000000 -739000000 -429000000 -1071000000 1027000000 696000000 3700000000 4829000000 -7126000000 -6733000000 1506000000 1493000000 152000000 175000000 -8480000000 -8051000000 6709000000 9882000000 338000000 288000000 472000000 500000000 6499000000 6218000000 3847000000 3805000000 888000000 680000000 1915000000 1688000000 6650000000 6173000000 2468000000 2663000000 22664000000 25224000000 788000000 766000000 21111000000 20212000000 11559000000 11050000000 9552000000 9162000000 9282000000 10454000000 23277000000 22799000000 6527000000 6033000000 72090000000 74438000000 3961000000 4607000000 1479000000 1556000000 5347000000 5845000000 886000000 887000000 318000000 343000000 1051000000 2251000000 13042000000 15489000000 14477000000 14522000000 6877000000 7522000000 1 1 1000000 1000000 0 0 0 0 2400000000 2400000000 1987305154 1986519278 24727000000 24709000000 251246618 248724257 15686000000 15229000000 36920000000 35257000000 -8480000000 -8051000000 37481000000 36686000000 213000000 219000000 37694000000 36905000000 72090000000 74438000000 1987181491 1985676735 24612000000 24429000000 123663 242705 6000000 12000000 116000000 123000000 -7000000 -4000000 1987305154 1985919440 24727000000 24560000000 251823511 234456992 -15722000000 -13720000000 579159 528436 36000000 31000000 2266 8417107 0 866000000 251246618 242345663 -15686000000 -14555000000 36355000000 34487000000 1436000000 1435000000 0.51 0.47 889000000 822000000 -18000000 -15000000 36920000000 35115000000 -8071000000 -8706000000 -409000000 -739000000 -8480000000 -9445000000 230000000 226000000 -17000000 -17000000 213000000 209000000 1986519278 1985273421 24709000000 24470000000 785876 646019 36000000 36000000 531000000 572000000 -549000000 -518000000 1987305154 1985919440 24727000000 24560000000 248724257 221191228 -15229000000 -11822000000 4669629 4808575 288000000 261000000 7191990 25963010 745000000 2994000000 251246618 242345663 -15686000000 -14555000000 35257000000 31528000000 4129000000 5900000000 1.53 1.41 2668000000 2475000000 -202000000 -162000000 36920000000 35115000000 -8051000000 -8374000000 -429000000 -1071000000 -8480000000 -9445000000 219000000 222000000 -6000000 -13000000 213000000 209000000 4129000000 5900000000 945000000 943000000 1485000000 1517000000 530000000 570000000 424000000 409000000 527000000 1224000000 1915000000 42000000 4223000000 7255000000 1447000000 1167000000 877000000 0 40000000 48000000 45000000 3000000 -20000000 -14000000 -2309000000 -1108000000 -90000000 37000000 1000000 7000000 1447000000 753000000 968000000 3110000000 133000000 126000000 2668000000 2486000000 -5039000000 -6179000000 -48000000 -173000000 -3173000000 -205000000 9882000000 9799000000 6709000000 9594000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1 — Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 — New Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Recently Adopted Accounting Standards</span></div>In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements. Recently Adopted Accounting StandardsIn September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 — Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,073 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,711 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,641 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,694 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,817 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,326 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,864 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,328 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,503 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,923 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.2 billion in the Diagnostics segment and approximately $456 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contract Assets and Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4 4 4 4 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,073 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,711 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,641 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,694 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,817 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,326 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,309 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,864 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,328 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,503 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,365 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,923 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.</span></div> 0 987000000 987000000 0 1001000000 1001000000 0 381000000 381000000 0 325000000 325000000 0 1368000000 1368000000 0 1326000000 1326000000 506000000 495000000 1001000000 357000000 470000000 827000000 354000000 718000000 1072000000 329000000 639000000 968000000 860000000 1213000000 2073000000 686000000 1109000000 1795000000 317000000 997000000 1314000000 281000000 938000000 1219000000 38000000 95000000 133000000 65000000 118000000 183000000 97000000 43000000 140000000 92000000 35000000 127000000 561000000 301000000 862000000 1273000000 839000000 2112000000 1013000000 1436000000 2449000000 1711000000 1930000000 3641000000 271000000 292000000 563000000 263000000 270000000 533000000 246000000 298000000 544000000 225000000 244000000 469000000 217000000 67000000 284000000 207000000 51000000 258000000 251000000 421000000 672000000 213000000 393000000 606000000 223000000 264000000 487000000 207000000 213000000 420000000 188000000 39000000 227000000 156000000 36000000 192000000 544000000 928000000 1472000000 423000000 744000000 1167000000 1940000000 2309000000 4249000000 1694000000 1951000000 3645000000 4000000 0 4000000 3000000 0 3000000 3817000000 6326000000 10143000000 4094000000 6316000000 10410000000 0 2889000000 2889000000 0 2853000000 2853000000 0 955000000 955000000 0 843000000 843000000 0 3844000000 3844000000 0 3696000000 3696000000 1472000000 1477000000 2949000000 1108000000 1491000000 2599000000 1081000000 2086000000 3167000000 1016000000 2027000000 3043000000 2553000000 3563000000 6116000000 2124000000 3518000000 5642000000 917000000 2872000000 3789000000 836000000 2788000000 3624000000 128000000 293000000 421000000 308000000 507000000 815000000 289000000 127000000 416000000 284000000 110000000 394000000 1975000000 853000000 2828000000 5436000000 2923000000 8359000000 3309000000 4145000000 7454000000 6864000000 6328000000 13192000000 800000000 873000000 1673000000 775000000 830000000 1605000000 729000000 873000000 1602000000 667000000 773000000 1440000000 661000000 199000000 860000000 610000000 167000000 777000000 733000000 1271000000 2004000000 650000000 1228000000 1878000000 652000000 794000000 1446000000 604000000 667000000 1271000000 528000000 122000000 650000000 456000000 112000000 568000000 1528000000 2681000000 4209000000 1165000000 2320000000 3485000000 5631000000 6813000000 12444000000 4927000000 6097000000 11024000000 10000000 0 10000000 8000000 0 8000000 11503000000 18365000000 29868000000 13923000000 19639000000 33562000000 -30000000 30000000 87000000 -87000000 4200000000 456000000 0.59 P24M 0.17 P12M <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 500000000 346000000 292000000 554000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 — Supplemental Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2023 and 2022 were $1.431 billion and $1.429 billion, respectively, and for the nine months ended September 30, 2023 and 2022 were $4.113 billion and $5.876 billion, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2023 includes $302 million of pension contributions and the payment of cash taxes of approximately $1.180 billion. The first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2023 related to the allowance for doubtful accounts as of September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September 30, 2023 and December 31, 2022 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Abbott’s long-term investments as of September 30, 2023 versus the balance as of December 31, 2022 is primarily due to investments acquired as part of a business acquisition and other additional investments, partially offset by the impact of equity method investment losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s equity securities as of September 30, 2023 include $291 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott also holds certain investments as of September 30, 2023 with a carrying value of $175 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $87 million that do not have a readily determinable fair value.</span></div> 1431000000 1429000000 4113000000 5876000000 302000000 1180000000 362000000 987000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2023 related to the allowance for doubtful accounts as of September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 262000000 22000000 25000000 259000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September 30, 2023 and December 31, 2022 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 566000000 558000000 222000000 208000000 788000000 766000000 291000000 175000000 87000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(480)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(480)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,506)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -6646000000 -6260000000 -1497000000 -2554000000 72000000 108000000 -497000000 -1008000000 -9000000 15000000 96000000 278000000 -17000000 0 0 -41000000 16000000 65000000 -480000000 -1008000000 -9000000 56000000 80000000 213000000 -7126000000 -7268000000 -1506000000 -2498000000 152000000 321000000 -6733000000 -5839000000 -1493000000 -2670000000 175000000 135000000 -410000000 -1429000000 -6000000 45000000 134000000 289000000 -17000000 0 7000000 -127000000 157000000 103000000 -393000000 -1429000000 -13000000 172000000 -23000000 186000000 -7126000000 -7268000000 -1506000000 -2498000000 152000000 321000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 6 — Business Acquisitions </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management even more personal and precise. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings. </span></div>The preliminary allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets of $305 million; non-deductible in-process research and development of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $384 million; net deferred tax assets of approximately $31 million and other net assets of approximately $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts. 20 851000000 2 305000000 15000000 384000000 31000000 116000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 7 — Goodwill and Intangible Assets </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of goodwill reported was $23.3 billion at September 30, 2023 and $22.8 billion at December 31, 2022. Recent business </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions increased goodwill by approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$590 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oreign currency translation adjustments decreased goodwill by approximately $112 million in the first nine months of 2023. The amount of goodwill related to reportable segments at September 30, 2023 was $2.6 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.8 billion for the Medical Devices segment. There were no reductions of goodwill relating to impairments in the first nine months of 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.2 billion as of September 30, 2023 and December 31, 2022, respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The gross amount of amortizable intangible assets increased by $305 million due to a recent business acquisition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization was $19.0 billion and $17.6 billion as of September 30, 2023 and December 31, 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments decreased intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by $14 million in the first nine months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which relate to in-process research and development (IPR&amp;D) acquired in a business combination, were approximately $832 million as of September 30, 2023 and $807 million as of December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Recent business acquisitions increased IPR&amp;D by $80 million. This increase was partially offset by $55 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.</span></div> 23300000000 22800000000 590000000 -112000000 2600000000 285000000 3500000000 16800000000 0 27500000000 27200000000 305000000 19000000000 17600000000 -14000000 2000000000 1900000000 1700000000 1600000000 1300000000 832000000 807000000 80000000 55000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 — Restructuring Plans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the nine months ended September 30, 2023, Abbott recorded employee related severance and other charges of approximately $102 million, of which approximately $31 million was recorded in Cost of products sold, approximately $16 million was recorded in Research and development, and approximately $55 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $29 million related to these restructuring plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 102000000 31000000 16000000 55000000 29000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 228000000 102000000 181000000 149000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 — Incentive Stock Programs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2023, Abbott granted 1,986,671 stock options, 463,856 restricted stock awards and 4,927,476 restricted stock units under its incentive stock program. At September 30, 2023, approximately 74 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2023 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,342,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,718,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized share-based compensation cost at September 30, 2023 amounted to approximately $560 million which is expected to be recognized over the next three years.</span></div> 1986671 463856 4927476 74000000 Information regarding the number of options outstanding and exercisable at September 30, 2023 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,342,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,718,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 29342041 24718236 P5Y P4Y3M18D 73.77 66.27 825000000 825000000 560000000 P3Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 — Debt and Lines of Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity. The repayment equated to approximately $1.2 billion. In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition. On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.</span></div> 1140000000 0.00875 1200000000 197000000 750000000 0.0255 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 — Financial Instruments, Derivatives and Fair Value Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.3 billion at September 30, 2023 and $7.7 billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next <span style="-sec-ix-hidden:f-834">twelve</span> to eighteen months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2023 and December 31, 2022, Abbott held the gross notional amounts of $14.2 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has designated a yen-denominated, 5-year term loan of approximately $401 million and $446 million as of September 30, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at September 30, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2023 and December 31, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A gain of $60 million and a loss of $27 million were recognized in the three months ended September 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. A loss of $4 million and a gain of $225 million were recognized in the first nine months ended September 30, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt was determined based on significant other observable inputs, including current interest rates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2022 reflects the impact of projected timeline changes for events that will trigger payment of contingent consideration, partially offset by additional contingent consideration due to a recent business acquisition. 7300000000 7700000000 P18M 14200000000 12000000000 P5Y P5Y 401000000 446000000 2900000000 2900000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, 2023 and December 31, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 0 0 158000000 136000000 0 0 13000000 20000000 254000000 304000000 63000000 96000000 113000000 108000000 115000000 130000000 401000000 446000000 367000000 412000000 750000000 828000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2023 and 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div> 125000000 350000000 152000000 442000000 22000000 79000000 211000000 149000000 12000000 24000000 45000000 108000000 -18000000 -85000000 -15000000 -253000000 60000000 -27000000 -4000000 225000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September 30, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 566000000 566000000 558000000 558000000 222000000 222000000 208000000 208000000 15528000000 14681000000 16773000000 16313000000 367000000 367000000 412000000 412000000 178000000 178000000 226000000 226000000 0 0 0 0 171000000 171000000 156000000 156000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 304000000 304000000 0 0 367000000 0 367000000 0 671000000 304000000 367000000 0 2702000000 0 2702000000 0 171000000 0 171000000 0 178000000 0 178000000 0 109000000 0 0 109000000 3160000000 0 3051000000 109000000 307000000 307000000 0 0 412000000 0 412000000 0 719000000 307000000 412000000 0 2691000000 0 2691000000 0 156000000 156000000 226000000 0 226000000 0 130000000 0 0 130000000 3203000000 0 3073000000 130000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 — Litigation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $25 million to $35 million. The recorded accrual balance at September 30, 2023 for these proceedings and exposures was approximately $30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.</span></div> 4000000 10000000 25000000 35000000 30000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 — Post-Employment Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailment gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2023 and 2022, $302 million and $362 million, respectively, were contributed to defined benefit plans. In the first nine months of 2023 and 2022, $28 million was contributed, in each year, to the post-employment medical and dental plans.</span></div> Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailment gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 56000000 92000000 174000000 282000000 10000000 13000000 29000000 38000000 114000000 74000000 342000000 225000000 15000000 9000000 45000000 27000000 244000000 231000000 729000000 701000000 6000000 8000000 18000000 23000000 0 0 14000000 0 0 0 0 0 -2000000 -58000000 -8000000 -174000000 1000000 -2000000 2000000 -8000000 1000000 0 1000000 1000000 -3000000 -6000000 -10000000 -18000000 -71000000 -7000000 -218000000 -19000000 15000000 10000000 44000000 32000000 302000000 362000000 28000000 28000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 14 — Taxes on Earnings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2023 and 2022, taxes on earnings include approximately $11 million and $36 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2023 and 2022, taxes on earnings also include approximately $59 million and $20 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $55 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott expects to file a petition with the U.S. Tax Court contesting the 2019 SNOD in December of 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organization for Economic Cooperation &amp; Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15% minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have indicated their intent to adopt the proposal and are drafting legislation to implement the Pillar 2 model rules with a subset of the rules becoming effective January 1, 2024, and the remaining rules becoming effective January 1, 2025, or in later periods. Abbott is also continuing to analyze the Pillar 2 model rules. Implementation of the OECD proposal may have a material impact on Abbott’s Condensed Consolidated Financial Statements in the future.</span></div> 11000000 36000000 59000000 20000000 55000000 417000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 15 — Segment Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s reportable segments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Established Pharmaceutical Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— International sales of a broad line of branded generic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nutritional Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of a broad line of adult and pediatric nutritional products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,671 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three and nine months ended September 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI and charges related to restructuring actions and intangible asset and investment impairments. Other, net for the nine months ended September 30, 2023 also includes income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment, $111 million of charges related to the impairment of IPR&amp;D intangible assets as well as integration costs related to the acquisition of Alere Inc. and restructuring charges. </span></div></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,645 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(530)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,671 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three and nine months ended September 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI and charges related to restructuring actions and intangible asset and investment impairments. Other, net for the nine months ended September 30, 2023 also includes income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment, $111 million of charges related to the impairment of IPR&amp;D intangible assets as well as integration costs related to the acquisition of Alere Inc. and restructuring charges. </span></div></td></tr></table></div> 1368000000 1326000000 3844000000 3696000000 345000000 331000000 952000000 831000000 2073000000 1795000000 6116000000 5642000000 284000000 69000000 972000000 550000000 2449000000 3641000000 7454000000 13192000000 632000000 1346000000 1720000000 5615000000 4249000000 3645000000 12444000000 11024000000 1342000000 1045000000 3805000000 3288000000 10139000000 10407000000 29858000000 33554000000 2603000000 2791000000 7449000000 10284000000 4000000 3000000 10000000 8000000 10143000000 10410000000 29868000000 33562000000 50000000 115000000 198000000 352000000 -69000000 -86000000 -182000000 -309000000 117000000 123000000 530000000 570000000 496000000 498000000 1485000000 1517000000 200000000 211000000 185000000 550000000 1671000000 1758000000 4869000000 6986000000 0.45 0.45 0.45 0.45 10000000 172000000 111000000 111000000 EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 469 265 1 false 78 0 false 7 false false R1.htm 0000001 - Document - Cover Sheet http://www.abbott.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited Condensed Consolidated Statement of Earnings (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited Condensed Consolidated Statement of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited Condensed Consolidated Balance Sheet (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/BasisofPresentation Basis of Presentation Notes 10 false false R11.htm 0000011 - Disclosure - New Accounting Standards Sheet http://www.abbott.com/role/NewAccountingStandards New Accounting Standards Notes 11 false false R12.htm 0000012 - Disclosure - Revenue Sheet http://www.abbott.com/role/Revenue Revenue Notes 12 false false R13.htm 0000013 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 13 false false R14.htm 0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss Changes In Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 0000015 - Disclosure - Business Acquisitions Sheet http://www.abbott.com/role/BusinessAcquisitions Business Acquisitions Notes 15 false false R16.htm 0000016 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 0000017 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/RestructuringPlans Restructuring Plans Notes 17 false false R18.htm 0000018 - Disclosure - Incentive Stock Programs Sheet http://www.abbott.com/role/IncentiveStockPrograms Incentive Stock Programs Notes 18 false false R19.htm 0000019 - Disclosure - Debt and Lines of Credit Sheet http://www.abbott.com/role/DebtandLinesofCredit Debt and Lines of Credit Notes 19 false false R20.htm 0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 20 false false R21.htm 0000021 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/LitigationandEnvironmentalMatters Litigation and Environmental Matters Notes 21 false false R22.htm 0000022 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/PostEmploymentBenefits Post-Employment Benefits Notes 22 false false R23.htm 0000023 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/TaxesonEarnings Taxes on Earnings Notes 23 false false R24.htm 0000024 - Disclosure - Segment Information Sheet http://www.abbott.com/role/SegmentInformation Segment Information Notes 24 false false R25.htm 9954471 - Disclosure - New Accounting Standards (Policies) Sheet http://www.abbott.com/role/NewAccountingStandardsPolicies New Accounting Standards (Policies) Policies http://www.abbott.com/role/NewAccountingStandards 25 false false R26.htm 9954472 - Disclosure - Revenue (Tables) Sheet http://www.abbott.com/role/RevenueTables Revenue (Tables) Tables http://www.abbott.com/role/Revenue 26 false false R27.htm 9954473 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/SupplementalFinancialInformation 27 false false R28.htm 9954474 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables Changes In Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss 28 false false R29.htm 9954475 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/RestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/RestructuringPlans 29 false false R30.htm 9954476 - Disclosure - Incentive Stock Programs (Tables) Sheet http://www.abbott.com/role/IncentiveStockProgramsTables Incentive Stock Programs (Tables) Tables http://www.abbott.com/role/IncentiveStockPrograms 30 false false R31.htm 9954477 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures 31 false false R32.htm 9954478 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/PostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/PostEmploymentBenefits 32 false false R33.htm 9954479 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/SegmentInformation 33 false false R34.htm 9954480 - Disclosure - Revenue - Narrative (Details) Sheet http://www.abbott.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 34 false false R35.htm 9954481 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details) Sheet http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails Revenue - Summary of Revenue by Sales Category (Details) Details 35 false false R36.htm 9954482 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details) Sheet http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails Revenue - Schedule of Changes in Contract Liabilities (Details) Details 36 false false R37.htm 9954483 - Disclosure - Supplemental Financial Information - Narrative (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails Supplemental Financial Information - Narrative (Details) Details 37 false false R38.htm 9954484 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Details 38 false false R39.htm 9954485 - Disclosure - Supplemental Financial Information - Investments (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails Supplemental Financial Information - Investments (Details) Details 39 false false R40.htm 9954486 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails Changes In Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables 40 false false R41.htm 9954487 - Disclosure - Business Acquisitions (Details) Sheet http://www.abbott.com/role/BusinessAcquisitionsDetails Business Acquisitions (Details) Details http://www.abbott.com/role/BusinessAcquisitions 41 false false R42.htm 9954488 - Disclosure - Goodwill and Intangible Assets (Details) Sheet http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails Goodwill and Intangible Assets (Details) Details http://www.abbott.com/role/GoodwillandIntangibleAssets 42 false false R43.htm 9954489 - Disclosure - Restructuring Plans - Narrative (Details) Sheet http://www.abbott.com/role/RestructuringPlansNarrativeDetails Restructuring Plans - Narrative (Details) Details 43 false false R44.htm 9954490 - Disclosure - Restructuring Plans - Restructuring Activity and Related Accruals (Details) Sheet http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails Restructuring Plans - Restructuring Activity and Related Accruals (Details) Details 44 false false R45.htm 9954491 - Disclosure - Incentive Stock Programs - Narrative (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails Incentive Stock Programs - Narrative (Details) Details 45 false false R46.htm 9954492 - Disclosure - Incentive Stock Programs - Options (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails Incentive Stock Programs - Options (Details) Details 46 false false R47.htm 9954493 - Disclosure - Debt and Lines of Credit (Details) Sheet http://www.abbott.com/role/DebtandLinesofCreditDetails Debt and Lines of Credit (Details) Details http://www.abbott.com/role/DebtandLinesofCredit 47 false false R48.htm 9954494 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) Details http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables 48 false false R49.htm 9954495 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) Details 49 false false R50.htm 9954496 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) Details 50 false false R51.htm 9954497 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Details 51 false false R52.htm 9954498 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Details 52 false false R53.htm 9954499 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/LitigationandEnvironmentalMatters 53 false false R54.htm 9954500 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details) Details 54 false false R55.htm 9954501 - Disclosure - Post-Employment Benefits - Narrative (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails Post-Employment Benefits - Narrative (Details) Details 55 false false R56.htm 9954502 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/TaxesonEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/TaxesonEarnings 56 false false R57.htm 9954503 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/SegmentInformationTables 57 false false All Reports Book All Reports abt-20230930.htm abt-20230930.xsd abt-20230930_cal.xml abt-20230930_def.xml abt-20230930_lab.xml abt-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abt-20230930.htm": { "nsprefix": "abt", "nsuri": "http://www.abbott.com/20230930", "dts": { "inline": { "local": [ "abt-20230930.htm" ] }, "schema": { "local": [ "abt-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd" ] }, "calculationLink": { "local": [ "abt-20230930_cal.xml" ] }, "definitionLink": { "local": [ "abt-20230930_def.xml" ] }, "labelLink": { "local": [ "abt-20230930_lab.xml" ] }, "presentationLink": { "local": [ "abt-20230930_pre.xml" ] } }, "keyStandard": 244, "keyCustom": 21, "axisStandard": 24, "axisCustom": 0, "memberStandard": 43, "memberCustom": 35, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://www.abbott.com/20230930": 1 }, "contextCount": 469, "entityCount": 1, "segmentCount": 78, "elementCount": 464, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1048, "http://xbrl.sec.gov/dei/2023": 32 }, "report": { "R1": { "role": "http://www.abbott.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)", "shortName": "Condensed Consolidated Statement of Earnings (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R3": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "longName": "0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R4": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical", "longName": "0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)", "shortName": "Condensed Consolidated Balance Sheet (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "longName": "0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R8": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R9": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "longName": "0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R10": { "role": "http://www.abbott.com/role/BasisofPresentation", "longName": "0000010 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.abbott.com/role/NewAccountingStandards", "longName": "0000011 - Disclosure - New Accounting Standards", "shortName": "New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.abbott.com/role/Revenue", "longName": "0000012 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.abbott.com/role/SupplementalFinancialInformation", "longName": "0000013 - Disclosure - Supplemental Financial Information", "shortName": "Supplemental Financial Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss", "longName": "0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss)", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.abbott.com/role/BusinessAcquisitions", "longName": "0000015 - Disclosure - Business Acquisitions", "shortName": "Business Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.abbott.com/role/GoodwillandIntangibleAssets", "longName": "0000016 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.abbott.com/role/RestructuringPlans", "longName": "0000017 - Disclosure - Restructuring Plans", "shortName": "Restructuring Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.abbott.com/role/IncentiveStockPrograms", "longName": "0000018 - Disclosure - Incentive Stock Programs", "shortName": "Incentive Stock Programs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.abbott.com/role/DebtandLinesofCredit", "longName": "0000019 - Disclosure - Debt and Lines of Credit", "shortName": "Debt and Lines of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures", "longName": "0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures", "shortName": "Financial Instruments, Derivatives and Fair Value Measures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.abbott.com/role/LitigationandEnvironmentalMatters", "longName": "0000021 - Disclosure - Litigation and Environmental Matters", "shortName": "Litigation and Environmental Matters", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.abbott.com/role/PostEmploymentBenefits", "longName": "0000022 - Disclosure - Post-Employment Benefits", "shortName": "Post-Employment Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.abbott.com/role/TaxesonEarnings", "longName": "0000023 - Disclosure - Taxes on Earnings", "shortName": "Taxes on Earnings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.abbott.com/role/SegmentInformation", "longName": "0000024 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.abbott.com/role/NewAccountingStandardsPolicies", "longName": "9954471 - Disclosure - New Accounting Standards (Policies)", "shortName": "New Accounting Standards (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.abbott.com/role/RevenueTables", "longName": "9954472 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationTables", "longName": "9954473 - Disclosure - Supplemental Financial Information (Tables)", "shortName": "Supplemental Financial Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954474 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.abbott.com/role/RestructuringPlansTables", "longName": "9954475 - Disclosure - Restructuring Plans (Tables)", "shortName": "Restructuring Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.abbott.com/role/IncentiveStockProgramsTables", "longName": "9954476 - Disclosure - Incentive Stock Programs (Tables)", "shortName": "Incentive Stock Programs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables", "longName": "9954477 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.abbott.com/role/PostEmploymentBenefitsTables", "longName": "9954478 - Disclosure - Post-Employment Benefits (Tables)", "shortName": "Post-Employment Benefits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.abbott.com/role/SegmentInformationTables", "longName": "9954479 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.abbott.com/role/RevenueNarrativeDetails", "longName": "9954480 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "longName": "9954481 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details)", "shortName": "Revenue - Summary of Revenue by Sales Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-181", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R36": { "role": "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails", "longName": "9954482 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details)", "shortName": "Revenue - Schedule of Changes in Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails", "longName": "9954483 - Disclosure - Supplemental Financial Information - Narrative (Details)", "shortName": "Supplemental Financial Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails", "longName": "9954484 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "shortName": "Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "longName": "9954485 - Disclosure - Supplemental Financial Information - Investments (Details)", "shortName": "Supplemental Financial Information - Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-323", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R40": { "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954486 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-326", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R41": { "role": "http://www.abbott.com/role/BusinessAcquisitionsDetails", "longName": "9954487 - Disclosure - Business Acquisitions (Details)", "shortName": "Business Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-356", "name": "us-gaap:BusinessAcquisitionSharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R42": { "role": "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Goodwill and Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R43": { "role": "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "longName": "9954489 - Disclosure - Restructuring Plans - Narrative (Details)", "shortName": "Restructuring Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-361", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-361", "name": "us-gaap:TangibleAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R44": { "role": "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails", "longName": "9954490 - Disclosure - Restructuring Plans - Restructuring Activity and Related Accruals (Details)", "shortName": "Restructuring Plans - Restructuring Activity and Related Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-365", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-365", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "longName": "9954491 - Disclosure - Incentive Stock Programs - Narrative (Details)", "shortName": "Incentive Stock Programs - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails", "longName": "9954492 - Disclosure - Incentive Stock Programs - Options (Details)", "shortName": "Incentive Stock Programs - Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-370", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-370", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.abbott.com/role/DebtandLinesofCreditDetails", "longName": "9954493 - Disclosure - Debt and Lines of Credit (Details)", "shortName": "Debt and Lines of Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-373", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-373", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "longName": "9954494 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-382", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtInstrumentTerm", "span", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R49": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "longName": "9954495 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-387", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R50": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "longName": "9954496 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-405", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-405", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "longName": "9954497 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-429", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R52": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "longName": "9954498 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-442", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-442", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "longName": "9954499 - Disclosure - Litigation and Environmental Matters (Details)", "shortName": "Litigation and Environmental Matters (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "longName": "9954500 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details)", "shortName": "Post-Employment Benefits - Schedule of Net Periodic Benefit Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-452", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-452", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "longName": "9954501 - Disclosure - Post-Employment Benefits - Narrative (Details)", "shortName": "Post-Employment Benefits - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-319", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-456", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } }, "R56": { "role": "http://www.abbott.com/role/TaxesonEarningsDetails", "longName": "9954502 - Disclosure - Taxes on Earnings (Details)", "shortName": "Taxes on Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "abt:ExcessTaxBenefitFromShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abt:ExcessTaxBenefitFromShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.abbott.com/role/SegmentInformationDetails", "longName": "9954503 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20230930.htm", "unique": true } } }, "tag": { "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document and Entity Information", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in in-process R&D due to acquisition", "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r144" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r14", "r60" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r27", "r285", "r286", "r287", "r288", "r294", "r847" ] }, "us-gaap_CommonStockSharesHeldInEmployeeTrust": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesHeldInEmployeeTrust", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in mutual funds held in a rabbi trust", "label": "Common Stock, Shares Held in Employee Trust", "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r823" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r348", "r349", "r350", "r351", "r438", "r478", "r507", "r508", "r509", "r603", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r808", "r855", "r861", "r875", "r876", "r877", "r878", "r879" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCredit" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Lines of Credit", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r148", "r227", "r367", "r373", "r374", "r375", "r376", "r377", "r378", "r383", "r390", "r391", "r393" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r825" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating cost and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r129" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMatters" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation and Environmental Matters", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r147", "r345", "r346", "r759", "r856" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r348", "r349", "r350", "r351", "r478", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r861", "r874", "r875", "r876", "r877", "r878", "r879" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r348", "r349", "r350", "r351", "r438", "r478", "r507", "r508", "r509", "r603", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r808", "r855", "r861", "r875", "r876", "r877", "r878", "r879" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating earnings", "terseLabel": "Operating Earnings", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r271", "r285", "r291", "r294", "r782" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r826" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r132" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed asset impairment charges", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r115", "r146" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r348", "r349", "r350", "r351", "r478", "r604", "r643", "r678", "r679", "r734", "r736", "r738", "r739", "r751", "r769", "r770", "r783", "r790", "r802", "r805", "r861", "r874", "r875", "r876", "r877", "r878", "r879" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r888", "r890", "r891", "r892" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r74", "r118", "r119", "r151" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r182", "r231", "r232", "r233", "r236", "r237", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r265", "r310", "r311", "r527", "r559", "r561", "r562", "r563", "r594", "r597", "r598", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r182", "r231", "r232", "r233", "r236", "r237", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r265", "r310", "r311", "r527", "r559", "r561", "r562", "r563", "r594", "r597", "r598", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r839" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r174" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r568", "r569", "r572" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared on common shares (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r151" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, at Fair Value", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r827" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Balances", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r567", "r573" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold, excluding amortization of intangible assets", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r130", "r605" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r21", "r151" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r823" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r114", "r157", "r654", "r655" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r381", "r440", "r441", "r442", "r443", "r444", "r445", "r569", "r600", "r601", "r602", "r786", "r787", "r792", "r793", "r794" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r283", "r288", "r292", "r293", "r294", "r295", "r296", "r297", "r300" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings employed in the business", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r120", "r151", "r621", "r648", "r653", "r660", "r690", "r804" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r823" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r46", "r658" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r823" ] }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period, Reclassification, Adjustment", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]" } } }, "auth_ref": [ "r184" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.abbott.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r50", "r51", "r52", "r55" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r21", "r40", "r181", "r216", "r217", "r218", "r231", "r232", "r233", "r237", "r247", "r249", "r266", "r307", "r312", "r396", "r516", "r517", "r518", "r526", "r527", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r586", "r587", "r588", "r589", "r590", "r591", "r598", "r644", "r645", "r646", "r664", "r730" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r568", "r569", "r570", "r571", "r573" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r50", "r51", "r52", "r55" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r823" ] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring charges", "terseLabel": "Restructuring charges in 2023", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r91", "r96" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate intrinsic value of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r72" ] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, allowances", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r200", "r303", "r313" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments, Derivatives and Fair Value Measures", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r159", "r549", "r558" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r381", "r786", "r787" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) from foreign currency forward exchange contracts not designated as hedges", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r98", "r831" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r105", "r106" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r575" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r381", "r577", "r786", "r787" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r28" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Text Block Supplement [Abstract]", "label": "Disclosure Text Block Supplement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r21", "r66", "r151" ] }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other assets", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r135" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in goodwill due to acquisition", "label": "Goodwill, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r851" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r216", "r217", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r558" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value - Assets", "verboseLabel": "Receivable position", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r29", "r94", "r124", "r203", "r779" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r22", "r84", "r85", "r86", "r90", "r93", "r97", "r100", "r101", "r103", "r558" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExchangeDomain", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in intangible assets due to foreign currency translation adjustments", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r381", "r440", "r441", "r442", "r443", "r444", "r445", "r600", "r601", "r602", "r786", "r787", "r792", "r793", "r794" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r822" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r49", "r189", "r773" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r185", "r268", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r300", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r332", "r338", "r343", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r784", "r832", "r883" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "negatedLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r57", "r59" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r231", "r232", "r233", "r266", "r605", "r657", "r665", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r706", "r708", "r711", "r712", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r730", "r809" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Yen-denominated term loan", "terseLabel": "Fair Value - Liabilities", "negatedTerseLabel": "(Payable) position", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r29", "r94", "r124", "r203", "r779" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition share price (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration related to business combinations", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r3", "r80", "r538" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r824" ] }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedCashFlowStatementsCaptionsLineItems", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]", "label": "Condensed Cash Flow Statements, Captions [Line Items]" } } }, "auth_ref": [ "r230", "r829" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative foreign currency translation (loss) adjustments", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": [ "r204", "r206", "r208", "r209", "r576" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 Investment:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Common Stock Options Having No Dilutive Effect (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r264" ] }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap derivative financial instruments", "label": "Interest Rate Derivative Liabilities, at Fair Value", "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted Earnings Per Common Share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r222", "r240", "r241", "r243", "r244", "r246", "r255", "r261", "r262", "r263", "r265", "r562", "r563", "r613", "r630", "r781" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r36", "r188", "r228", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r540", "r542", "r543", "r578", "r804", "r859", "r872", "r873" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue recognized related to contract liability balance", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r410" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prior service cost (credit)", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r416", "r454", "r470", "r794", "r795" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r13" ] }, "abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "RevenueRemainingPerformanceObligationExpectedTimingPercentage", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of remaining performance obligation expected to be recognized in period", "label": "Revenue Remaining Performance Obligation Expected Timing Percentage", "documentation": "Represents the percentage of revenue recognized for remaining performance obligations." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailment gain", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r415", "r456", "r472" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r514" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial loss, net", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r416", "r453", "r469", "r794", "r795" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost - benefits earned during the period", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r418", "r450", "r466", "r794", "r795" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r92", "r95", "r97", "r99", "r676", "r679", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r717", "r718", "r719", "r720", "r723", "r724", "r725", "r726", "r743", "r744", "r747", "r748", "r779", "r806", "r808" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r217", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r511", "r519" ] }, "us-gaap_OtherAggregatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAggregatedInvestmentsMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Security Investments [Member]", "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests." } } }, "auth_ref": [ "r669", "r670", "r740" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities \u2014", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial (losses) and prior service (costs) and credits", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r8", "r44", "r864" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest Rate Hedge Contracts", "terseLabel": "Interest Rate Swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r771", "r813", "r814" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pension contributions", "terseLabel": "Company contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r431", "r440", "r473", "r792", "r793", "r794", "r795" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive stock program, shares reserved for future grants (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r72" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Post-Employment Benefits", "label": "Postemployment Benefits Disclosure [Text Block]", "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated." } } }, "auth_ref": [ "r412", "r413" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.abbott.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r180", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r411" ] }, "abt_KeyEmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "KeyEmergingMarketsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key Emerging Markets", "label": "Key Emerging Markets [Member]", "documentation": "It represents the key emerging markets, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails", "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r76", "r77", "r536", "r796", "r799" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r16", "r68", "r69", "r70", "r71" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails", "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r536", "r796", "r799" ] }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from business dispositions", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities." } } }, "auth_ref": [ "r830" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r109", "r171", "r219", "r275", "r592", "r714", "r819", "r885" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options outstanding, number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r488", "r489" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options outstanding, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r488", "r489" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r76", "r77", "r536" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade receivables, less allowances of $472 in 2023 and $500 in 2022", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r301", "r302" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable options, number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r490" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r536" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable options, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r490" ] }, "abt_CostOfGoodsAndServicesSoldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "CostOfGoodsAndServicesSoldMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold [Member]", "documentation": "Cost of Goods and Services Sold" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r416", "r452", "r468", "r794", "r795" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.abbott.com/role/RestructuringPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Activity and Related Accruals", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost on projected benefit obligations", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r416", "r420", "r451", "r467", "r794", "r795" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33", "r34" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cost (credit)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r449", "r465", "r794", "r795" ] }, "abt_CardiovascularSystemsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "CardiovascularSystemsIncMember", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CSI", "label": "Cardiovascular Systems, Inc. [Member]", "documentation": "Cardiovascular Systems, Inc." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r481", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive Common Stock Options (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r256", "r257", "r258", "r263", "r483" ] }, "abt_ElectrophysiologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "ElectrophysiologyMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Electrophysiology", "label": "Electrophysiology [Member]", "documentation": "It represents the electrophysiology, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r481", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "abt_DiabetesCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "DiabetesCareMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diabetes Care", "label": "Diabetes Care [Member]", "documentation": "It represents the Diabetes Care, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r862" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash From (Used in) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r225" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "abt_OtherEmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "OtherEmergingMarketsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Emerging Markets [Member]", "documentation": "Other Emerging Markets" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash From (Used in) Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r225" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, wages and commissions", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r104" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r104" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r197" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PostemploymentBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Postemployment Benefits [Abstract]", "label": "Postemployment Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRecallExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRecallExpense", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory recall expense", "label": "Inventory Recall Expense", "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise." } } }, "auth_ref": [ "r131" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r268", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r300", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r338", "r343", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r784", "r832", "r883" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r676", "r679", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r717", "r718", "r719", "r720", "r723", "r724", "r725", "r726", "r743", "r744", "r747", "r748", "r806", "r808" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units granted during period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r23" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow From (Used in) Financing Activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r37", "r369" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow From (Used in) Investing Activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r341", "r342", "r343" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash From Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r136", "r137", "r138" ] }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in amortizable intangible assets due to acquisition", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r22" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow From (Used in) Operating Activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r21", "r119", "r151" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation gain (loss) adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r11", "r19", "r158" ] }, "srt_CondensedCashFlowStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedCashFlowStatementTable", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Cash Flow Statement [Table]", "label": "Condensed Cash Flow Statement [Table]" } } }, "auth_ref": [ "r230", "r829" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r568", "r569" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r865", "r866" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r92", "r97", "r547" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r667", "r669", "r670", "r673", "r677", "r733", "r735", "r737", "r741", "r742", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r808" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r547" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r846" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r22", "r92", "r97" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r22", "r92", "r97", "r99", "r102", "r103", "r547" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r198" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r22", "r547" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r38", "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r593", "r785", "r786", "r787", "r788", "r789", "r841" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred tax assets", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } }, "auth_ref": [ "r79" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r13" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Shareholders' Investment", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r123", "r165", "r623", "r804", "r842", "r849", "r868" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r823" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Investment", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r294" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock options exercised", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r10", "r26" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net of amortization", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r56", "r58" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Finished products", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r140", "r776" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.abbott.com/role/IncentiveStockPrograms" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive Stock Programs", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r480", "r484", "r512", "r513", "r515", "r803" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r53" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r140", "r777" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r32", "r163", "r380", "r394", "r786", "r787", "r881" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r140", "r778" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "netLabel": "Total", "verboseLabel": "Long-term Investment Securities:", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r190" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r823" ] }, "abt_PrepaidExpenseAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PrepaidExpenseAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other receivables", "label": "Prepaid Expense and Other Receivables", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r11", "r19", "r158", "r212", "r215" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r593", "r785", "r786", "r787", "r788", "r789", "r841" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r32", "r116", "r117", "r161", "r163", "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r593", "r785", "r786", "r787", "r788", "r789", "r841" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross amount of amortizable intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r142", "r609" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards granted during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r499" ] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(1) and $(4) in 2023 and $11 and $36 in 2022", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r8", "r19", "r126", "r158" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Amounts and Location of Derivative Financial Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r93" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r38", "r64", "r65", "r107", "r108", "r110", "r112", "r149", "r150", "r230", "r368", "r369", "r370", "r371", "r372", "r374", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r392", "r593", "r785", "r786", "r787", "r788", "r789", "r841" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": [ "r79" ] }, "us-gaap_DebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt [Member]", "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r17" ] }, "us-gaap_PaymentsForOtherTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForOtherTaxes", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of cash taxes", "label": "Payments for Other Taxes", "documentation": "Amount of cash outflow for taxes classified as other." } } }, "auth_ref": [ "r12" ] }, "abt_RhythmManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "RhythmManagementMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rhythm Management", "label": "Rhythm Management [Member]", "documentation": "It represents the rhythm management, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r347", "r348", "r349", "r353", "r857", "r858" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r806", "r807", "r808", "r810", "r811", "r812", "r815", "r843", "r844", "r867", "r884", "r886" ] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XCHI", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "CHICAGO STOCK EXCHANGE, INC", "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of common shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r47" ] }, "abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests\u2019 share of income, business combinations, net of distributions and share repurchases", "label": "Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations", "documentation": "This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r48", "r659" ] }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities", "documentation": "Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer." } } }, "auth_ref": [] }, "abt_PrepaidExpenseAndOtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PrepaidExpenseAndOtherReceivablesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other receivables", "label": "Prepaid Expense and Other Receivables [Member]", "documentation": "The Other Prepaid Expenses and Receivables line item in the statement of financial position in which the amounts are included." } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r117", "r162" ] }, "abt_PointOfCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PointOfCareMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Point of Care", "label": "Point of Care [Member]", "documentation": "It represents the point of care, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r30", "r104", "r381", "r786", "r787" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options granted during the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r492" ] }, "abt_OtherAccruedLiabilitiesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "OtherAccruedLiabilitiesCurrentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current [Member]", "documentation": "Other Accrued Liabilities, Current" } } }, "auth_ref": [] }, "abt_GoodwillAndIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "GoodwillAndIntangibleAssetsLineItems", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets [Line Items]", "label": "Goodwill and Intangible Assets [Line Items]", "documentation": "Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on earnings", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r172", "r178", "r248", "r249", "r279", "r522", "r532", "r631" ] }, "abt_RestructuringReservePeriodCashSettledAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments and other adjustments", "label": "Restructuring Reserve Period Cash Settled and Other Adjustments", "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period." } } }, "auth_ref": [] }, "abt_ScheduleOfLongTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "ScheduleOfLongTermInvestmentsTableTextBlock", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Investments", "label": "Schedule of Long Term Investments [Table Text Block]", "documentation": "Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [] }, "abt_OtherCostAndExpenseOperatingAndNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "OtherCostAndExpenseOperatingAndNonoperating", "crdr": "debit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Cost and Expense, Operating and Nonoperating", "documentation": "The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses." } } }, "auth_ref": [] }, "abt_ScheduleOfGoodwillAndIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill and Intangible Assets [Table]", "label": "Schedule of Goodwill and Intangible Assets [Table]", "documentation": "Schedule of Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends declared on common shares", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r151" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options outstanding, weighted-average remaining life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r153" ] }, "abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions of businesses and technologies, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable options, weighted-average remaining life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r72" ] }, "abt_A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "A2022And2023RestructuringPlanStreamlineOfOperationsAndImproveEfficienciesForFourBusinessesMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses", "label": "2022 and 2023 Restructuring Plan, Streamline of Operations and Improve Efficiencies for Four Businesses [Member]", "documentation": "The entity's 2022 and 2023 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses." } } }, "auth_ref": [] }, "abt_CorporateAndBenefitPlanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "CorporateAndBenefitPlanCosts", "crdr": "debit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Corporate functions and benefit plan costs", "label": "Corporate and Benefit Plan Costs", "documentation": "The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization of intangible assets", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r194", "r330" ] }, "abt_StJudeMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "StJudeMedicalMember", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "St. Jude Medical", "label": "St Jude Medical [Member]", "documentation": "Represents information relating to acquisition of St. Jude Medical, Inc." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net foreign exchange (gain) loss", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r582", "r583", "r584", "r585", "r727" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated other comprehensive income (loss)", "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r43", "r44", "r126", "r199", "r620", "r649", "r653" ] }, "abt_A0875LongTermNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "A0875LongTermNotesDue2023Member", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.875% Long-term Notes Due 2023", "label": "0.875% Long-term Notes Due 2023 [Member]", "documentation": "0.875% Long-term Notes Due 2023" } } }, "auth_ref": [] }, "abt_DiagnosticProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "DiagnosticProductsMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diagnostics", "verboseLabel": "Diagnostic Products", "label": "Diagnostic Products [Member]", "documentation": "The diagnostics products segment of the entity." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r78", "r79" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r61", "r192", "r624" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r47" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other net assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r79" ] }, "abt_LongTermDebtExcludingCurrentMaturitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "LongTermDebtExcludingCurrentMaturitiesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities [Member]", "documentation": "Long-Term Debt, Excluding Current Maturities" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r49", "r136", "r226" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r141" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "crdr": "debit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency forward exchange contracts", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments." } } }, "auth_ref": [ "r95" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r304" ] }, "abt_HeartFailureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "HeartFailureMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heart Failure", "label": "Heart Failure [Member]", "documentation": "It represents the Heart Failure, segment of the entity." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "abt_DefinedBenefitPlanNetAmortizationCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "DefinedBenefitPlanNetAmortizationCostsAbstract", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net amortization of:", "label": "Defined Benefit Plan Net Amortization Costs [Abstract]", "documentation": "No definition available." } } }, "auth_ref": [] }, "abt_MolecularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "MolecularMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Molecular", "label": "Molecular [Member]", "documentation": "It represents the molecular, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r136" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r160", "r195", "r228", "r271", "r286", "r292", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r539", "r542", "r578", "r616", "r701", "r804", "r821", "r859", "r860", "r872" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual share-based awards recognized in first quarter (as a percent)", "label": "Annual Share Based Awards Recognized in First Quarter Percent", "documentation": "Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter." } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of reductions of goodwill relating to impairments", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r14", "r319", "r325", "r329", "r784" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r869" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency forward exchange contracts", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments." } } }, "auth_ref": [ "r95" ] }, "abt_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "RestrictedStockAwardsMember", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards", "label": "Restricted stock awards [Member]", "documentation": "Restricted stock awards." } } }, "auth_ref": [] }, "abt_FiveYearTermLoanDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "FiveYearTermLoanDue2024Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Year Term Loan due 2024", "label": "Five Year Term Loan due 2024 [Member]", "documentation": "Five Year Term Loan due 2024" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Shareholders\u2019 Investment", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r81", "r82", "r83", "r181", "r182", "r217", "r231", "r232", "r233", "r237", "r247", "r307", "r312", "r396", "r516", "r517", "r518", "r526", "r527", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r586", "r587", "r591", "r598", "r645", "r646", "r663", "r691", "r707", "r731", "r732", "r757", "r820", "r842", "r849", "r868", "r886" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Employed in the Business", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r181", "r231", "r232", "r233", "r237", "r247", "r249", "r307", "r312", "r516", "r517", "r518", "r526", "r527", "r551", "r553", "r554", "r557", "r561", "r644", "r646", "r664", "r886" ] }, "abt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNumberOfFiniteLivedIntangibles": { "xbrltype": "integerItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNumberOfFiniteLivedIntangibles", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of developed technology intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Actuarial (Losses) and Prior Service (Costs) and Credits", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r7", "r20", "r44", "r835", "r836", "r837" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue by Sales Category", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r863" ] }, "abt_PediatricNutritionalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PediatricNutritionalsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pediatric Nutritionals", "label": "Pediatric Nutritionals [Member]", "documentation": "It represents the pediatric nutritionals, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r22" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests in Subsidiaries", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r81", "r396", "r843", "r844", "r845", "r886" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitions" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r156", "r537" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments carrying value", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r281", "r305", "r833", "r848" ] }, "abt_CoreLaboratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "CoreLaboratoryMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Core Laboratory", "label": "Core Laboratory [Member]", "documentation": "It represents the core laboratory, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Foreign Currency Translation (Loss) Adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r6", "r20", "r44", "r217", "r218", "r587", "r588", "r589", "r590", "r591", "r835" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r21", "r181", "r216", "r217", "r218", "r231", "r232", "r233", "r237", "r247", "r249", "r266", "r307", "r312", "r396", "r516", "r517", "r518", "r526", "r527", "r551", "r552", "r553", "r554", "r555", "r557", "r561", "r586", "r587", "r588", "r589", "r590", "r591", "r598", "r644", "r645", "r646", "r664", "r730" ] }, "abt_PrepaidExpensesAndOtherReceivablesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PrepaidExpensesAndOtherReceivablesCurrentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other receivables, current", "label": "Prepaid Expenses and Other Receivables, Current [Member]", "documentation": "Prepaid Expenses and Other Receivables, Current" } } }, "auth_ref": [] }, "abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unearned revenue from cash received during the period", "label": "Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized", "documentation": "Amount of revenue recognized arising from contract liability from change in cash received to be satisfied." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r20", "r44", "r552", "r555", "r598", "r644", "r645", "r835", "r836", "r837", "r843", "r844", "r845" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r118", "r395" ] }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities [Member]", "documentation": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities" } } }, "auth_ref": [] }, "abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "LossContingencyRangeOfPossibleLossMaximumAggregateSites", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum expected cleanup exposure in aggregate", "label": "Loss Contingency Range of Possible Loss, Maximum Aggregate Sites", "documentation": "The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico." } } }, "auth_ref": [] }, "abt_BigfootBiomedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "BigfootBiomedicalMember", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bigfoot", "label": "Bigfoot Biomedical [Member]", "documentation": "Bigfoot Biomedical" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r331", "r337", "r713" ] }, "abt_IRSStatutoryNoticeOfDeficiencyClaimAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "IRSStatutoryNoticeOfDeficiencyClaimAmount", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax claim related to statutory notice of deficiency", "label": "IRS Statutory Notice of Deficiency, Claim Amount", "documentation": "IRS Statutory Notice of Deficiency, Claim Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r337", "r713" ] }, "abt_StructuralHeartMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "StructuralHeartMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Structural Heart", "label": "Structural Heart [Member]", "documentation": "It represents the structural heart, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r118", "r689" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r173" ] }, "abt_LegalProceedingsAndEnvironmentalExposuresMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "LegalProceedingsAndEnvironmentalExposuresMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal proceedings and environmental exposures", "label": "Legal proceedings and environmental exposures [Member]", "documentation": "Loss contingencies related to legal proceedings and environmental exposures." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r830", "r838" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r254", "r263" ] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XNYS", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK STOCK EXCHANGE, INC.", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] }, "abt_RapidDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "RapidDiagnosticsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rapid Diagnostics", "label": "Rapid Diagnostics [Member]", "documentation": "It represents the rapid diagnostics, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r54", "r816", "r817", "r818", "r889" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r252", "r263" ] }, "abt_EstablishedPharmaceuticalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "EstablishedPharmaceuticalProductsMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Established Pharmaceutical Products", "label": "Established Pharmaceutical Products [Member]", "documentation": "Represents Established Pharmaceutical Products, segment of the entity." } } }, "auth_ref": [] }, "abt_AdultNutritionalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "AdultNutritionalsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adult Nutritionals", "label": "Adult Nutritionals [Member]", "documentation": "It represents the adult nutritionals, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r118", "r395" ] }, "abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms": { "xbrltype": "sharesItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "StockIssuedDuringPeriodSharesIncentiveStockPrograms", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Issued under incentive stock programs (in shares)", "label": "Stock Issued During Period, Shares, Incentive Stock Programs", "documentation": "Stock Issued During Period, Shares, Incentive Stock Programs" } } }, "auth_ref": [] }, "abt_A255LongTermNotesDue2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "A255LongTermNotesDue2022Member", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.55% Long-term Notes Due 2022", "label": "2.55% Long-term Notes Due 2022 [Member]", "documentation": "2.55% Long-term Notes Due 2022" } } }, "auth_ref": [] }, "abt_OtherComprehensiveIncomeLossFairValueHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "OtherComprehensiveIncomeLossFairValueHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges", "label": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax" } } }, "auth_ref": [] }, "abt_VascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "VascularMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vascular", "label": "Vascular [Member]", "documentation": "It represents the vascular products, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "abt_EffectOfCommonAndTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "EffectOfCommonAndTreasuryShareTransactions", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect of common and treasury share transactions", "label": "Effect of Common and Treasury Share Transactions", "documentation": "This element represents the effect on retained earning due to common and treasury stock transactions." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings allocated to common shares", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r224", "r240", "r241", "r243", "r244", "r252", "r253", "r260", "r263", "r271", "r285", "r291", "r294", "r782" ] }, "abt_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other assets", "label": "Deferred Income Taxes and Other Assets, Noncurrent [Member]", "documentation": "The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included." } } }, "auth_ref": [] }, "abt_MedicalDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "MedicalDevicesMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Devices", "label": "Medical Devices [Member]", "documentation": "The medical devices segment of the entity." } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred shares, one dollar par value Authorized \u2014 1,000,000 shares, none issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r118", "r618", "r804" ] }, "abt_MinimumLengthOfTimeHedgedInCashFlowHedge": { "xbrltype": "durationItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "MinimumLengthOfTimeHedgedInCashFlowHedge", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold", "label": "Minimum Length Of Time Hedged In Cash Flow Hedge", "documentation": "Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "abt_ContractLiabilitiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "ContractLiabilitiesRollForward", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liabilities:", "label": "Contract Liabilities [Roll Forward]", "documentation": "Contract Liabilities" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in accumulated other comprehensive income (loss), net of income taxes", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Earnings", "verboseLabel": "Net Earnings", "terseLabel": "Net earnings", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r128", "r138", "r169", "r186", "r211", "r214", "r218", "r228", "r236", "r240", "r241", "r243", "r244", "r248", "r249", "r259", "r271", "r285", "r291", "r294", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r563", "r578", "r627", "r709", "r728", "r729", "r782", "r819", "r859" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r193", "r318", "r610", "r784", "r804", "r852", "r853" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r87" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings before taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r127", "r168", "r271", "r285", "r291", "r294", "r614", "r626", "r782" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net interest expense", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r170" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Changes In Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r125", "r220", "r611", "r628" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/TaxesonEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Earnings", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r229", "r521", "r523", "r524", "r525", "r531", "r533", "r534", "r535", "r661" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r113", "r520", "r880" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets related to in-process R&D acquired in a business combination", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r144" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r546" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r89" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Forward Exchange Contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r695", "r699", "r704", "r719", "r725", "r745", "r746", "r747", "r808" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r88" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r200", "r303", "r313", "r314", "r317", "r882" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts charged off and other deductions", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r316" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r201", "r774", "r804" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r479", "r794", "r795", "r799", "r800", "r801" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories:", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncontrolling Interests in Subsidiaries", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r42", "r164", "r228", "r306", "r354", "r357", "r358", "r359", "r365", "r366", "r578", "r622", "r691" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r45", "r213", "r215", "r221", "r612", "r629" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Allowance for Doubtful Accounts Activity", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r850" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r298", "r299", "r668", "r672", "r674", "r735", "r737", "r742", "r752", "r758", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r772", "r791", "r808", "r863", "r883" ] }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r206" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r134" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r205", "r206", "r544", "r545", "r550" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicBenefitCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical and Dental Plans", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r794", "r795", "r796", "r797", "r798" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r230", "r273", "r284", "r285", "r286", "r287", "r288", "r290", "r294", "r354", "r355", "r356", "r357", "r359", "r360", "r362", "r364", "r365", "r859", "r860" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromInvestments", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Sales (purchases) of other investment securities, net", "label": "Payments for (Proceeds from) Investments", "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r207" ] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfShortTermDebt", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net borrowings (repayments) of short-term debt and other", "label": "Proceeds from (Repayments of) Short-Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r209", "r217", "r218", "r541", "r780", "r835" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r230", "r273", "r284", "r285", "r286", "r287", "r288", "r290", "r294", "r354", "r355", "r356", "r357", "r359", "r360", "r362", "r364", "r365", "r859", "r860" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in goodwill due to foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r326" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r175", "r206", "r210" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Financial Information", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit)", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan." } } }, "auth_ref": [ "r8", "r9", "r158" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest (income)", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r133", "r274" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r44", "r870", "r871" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 and $(24) in 2023 and $50 and $96 in 2022", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r206" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r298", "r299", "r668", "r672", "r674", "r735", "r737", "r742", "r752", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r772", "r791", "r808", "r863", "r883" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r397", "r398", "r409" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r196", "r574", "r775" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Periodic Benefit Costs", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r152" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r347", "r348", "r349", "r353", "r857", "r858" ] }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r18" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r119" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r347", "r348", "r349", "r353", "r857", "r858" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r347", "r348", "r349", "r353", "r857", "r858" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Abbott Shareholders\u2019 Investment", "periodStartLabel": "Beginning of the period", "periodEndLabel": "End of the period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r119", "r121", "r122", "r139", "r691", "r707", "r731", "r732", "r804", "r821", "r842", "r849", "r868", "r886" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r166", "r167", "r834" ] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/RestructuringPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plans", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r333", "r334", "r336", "r339", "r344" ] }, "abt_NutritionalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "NutritionalProductsMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nutritionals", "verboseLabel": "Nutritional Products", "label": "Nutritional Products [Member]", "documentation": "The nutritional products segment of the entity." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common shares, without par value Authorized \u2014 2,400,000,000 shares Issued at stated capital amount \u2014 Shares: 2023: 1,987,305,154; 2022: 1,986,519,278", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r119", "r619", "r804" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of indefinite-lived intangible assets", "verboseLabel": "Impairment of IPR&D intangible assets", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r840", "r854" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Values and Fair Values of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r104", "r105" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r568", "r569", "r572" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r119", "r689" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r39", "r111", "r617", "r688" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r21", "r119", "r689", "r707", "r886", "r887" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, at Fair Value", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recorded accrual balance for legal proceedings and exposures", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r347", "r828" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "abt_ExcessTaxBenefitFromShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "ExcessTaxBenefitFromShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess tax benefits associated with share-based compensation", "label": "Excess Tax Benefit from Share-based Compensation", "documentation": "Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r341", "r342", "r343" ] }, "abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "LossContingencyRangeOfPossibleLossMaximumIndividualSite", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum expected cleanup exposure for individual site", "label": "Loss Contingency Range of Possible Loss, Maximum Individual Site", "documentation": "The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityandRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Accrued balance at beginning of the period", "periodEndLabel": "Accrued balance at end of the period", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r336", "r340" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r145", "r191", "r625" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts:", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Shareholders' Investment", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r187", "r202", "r228", "r306", "r354", "r355", "r357", "r358", "r359", "r361", "r363", "r365", "r366", "r539", "r542", "r578", "r804", "r859", "r860", "r872" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares Held in Treasury", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of hedged long-term debt", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r548" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net property and equipment", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r15", "r615", "r625", "r804" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Options Outstanding and Exercisable", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r25", "r73" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares held in treasury (in shares)", "periodStartLabel": "Beginning balance, treasury stock, common (in shares)", "periodEndLabel": "Ending balance, treasury stock, common (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease reasonably possible in gross unrecognized tax benefits", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r75" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Common shares held in treasury, at cost \u2014 Shares: 2023: 251,246,618; 2022: 248,724,257", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r41", "r66", "r67" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimation of possible loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r348", "r349", "r352", "r353" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r231", "r232", "r233", "r266", "r605", "r657", "r665", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r702", "r703", "r704", "r705", "r706", "r708", "r711", "r712", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r730", "r809" ] }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfInvestmentHoldingsTable", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Investment Holdings [Table]", "label": "Summary of Investment Holdings [Table]", "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period." } } }, "auth_ref": [ "r662", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r680", "r681", "r710", "r808" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.abbott.com/role/NewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, 2023", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfInvestmentHoldingsLineItems", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Investment Holdings [Line Items]", "label": "Summary of Investment Holdings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r662", "r666", "r667", "r668", "r669", "r670", "r671", "r673", "r674", "r675", "r676", "r677", "r680", "r681", "r710", "r808" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions/charges to income", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r223", "r315" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost, recognition period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r514" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r31", "r44", "r217", "r586", "r588", "r591", "r835" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected timing of satisfaction period (in months)", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r174" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r31", "r44", "r217", "r586", "r590", "r591", "r835" ] }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense from prior year tax positions", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement." } } }, "auth_ref": [ "r154", "r155" ] }, "abt_NeuromodulationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "NeuromodulationMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neuromodulation", "label": "Neuromodulation [Member]", "documentation": "It represents the neuromodulation, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r667", "r669", "r670", "r673", "r677", "r733", "r735", "r737", "r741", "r742", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r808" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r381", "r440", "r445", "r569", "r600", "r792", "r793", "r794" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Earnings Per Common Share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r222", "r240", "r241", "r243", "r244", "r246", "r252", "r255", "r261", "r262", "r263", "r265", "r562", "r563", "r613", "r630", "r781" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r381", "r440", "r445", "r569", "r601", "r786", "r787", "r792", "r793", "r794" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Net Sales to External Customers", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r272", "r273", "r284", "r289", "r290", "r296", "r298", "r300", "r407", "r408", "r605" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.abbott.com/role/NewAccountingStandards" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standards", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r176", "r177", "r179", "r183", "r234", "r235", "r238", "r239", "r250", "r251", "r308", "r309", "r528", "r529", "r530", "r556", "r560", "r564", "r565", "r566", "r579", "r580", "r581", "r595", "r596", "r599", "r606", "r607", "r608", "r648", "r649", "r650", "r651", "r653" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r381", "r440", "r441", "r442", "r443", "r444", "r445", "r569", "r602", "r786", "r787", "r792", "r793", "r794" ] }, "abt_StockIssuedDuringPeriodValueIncentiveStockPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20230930", "localname": "StockIssuedDuringPeriodValueIncentiveStockPrograms", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issued under incentive stock programs", "label": "Stock Issued During Period, Value, Incentive Stock Programs", "documentation": "Stock Issued During Period, Value, Incentive Stock Programs" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-10" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-8" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481565/712-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r828": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r829": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 76 0001628280-23-035957-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-035957-xbrl.zip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�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end